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INTRODUCTION 
 
Human Cytomegalovirus 
 
1.  CHARACTERISTIC FEATURES OF THE HERPESVIRUSES 
 
Human cytomegalovirus (HCMV) is a highly species specific herpes virus that infects and 
is carried by the majority of the human population. Herpesviruses are highly prevalent, 
affecting an estimated 70-100% of the world’s population. To this date, the human 
herpesvirus family consists of eight different members: herpes simplex virus 1 (HSV-1), 
herpes simplex virus 2 (HSV-2), varicella zoster virus (VZV), Epstein-Barr virus (EBV), 
human cytomegalovirus (HCMV) and human herpesviruses 6A, 6B, 7 and 8 (HHV6A, 
HHV6B, HHV7 and HHV8). The criteria for including a virus in the herpesvirus family is 
based on the architecture of the virion. A herpesvirus particle is composed of a core 
containing a linear double-stranded DNA molecule, which is enclosed within an 
icosadeltahedral capsid of 100 nm, containing 162 capsomers. The capsid is surrounded 
by a tegument layer which consists of amorphous protein material. In the mature virion, 
these structures are enclosed in a lipid bilayer envelope, which contains a number of viral 
glycoproteins on its surface. The mature virions range in size from 150-200 nm. 
All herpesviruses share four significant common properties: 1) they encode a large array 
of enzymes involved in nucleic acid metabolism, DNA synthesis, and processing of 
proteins such as thymidine kinase, DNA polymerase, helicase, primase and protein 
kinases; 2) the synthesis of viral DNA and the capsid assembly occurs in the nucleus of 
infected cells. Capsids are enveloped as the transit through the nuclear membrane and 
mature within the cytoplasm and intracellular compartments; 3) production of infectious 
progeny virus is mainly accompanied  by the destruction of the infected cells; 4) after 
primary infection, all herpesviruses persist in a latent state in their host and may be 
reactivated later in life. In cells harbouring latent virus, the viral genome appears in the 
form of  a closed circular structure, and few if any viral proteins are produced. 
Herpesvirus latency is established in different cell types; HSV-1, HSV-2 and VZV remain 
in a latent state in neurons of dorsal root ganglia, whereas latent EBV has been found 
primarily in memory B cells. HCMV establishes latency mainly in the myeloid cell 
lineage. For a herpesvirus to persist in its host, some general conditions must be fulfilled:   2
the virus must be able to infect cells without producing infectious progeny and therefore 
the virus infection cannot be cytopathic, host mechanisms must permit long-term 
maintenance of the viral genome, and the virus must be able to avoid elimination by the 
immune system. A delicate balance must therefore exist between the virus and its host to 
avoid virus elimination by the immune system or host destruction by the infection. 
Persistence in an immunocompetent host has  put an enormous evolutionary pressure on 
these viruses to develop strategies to avoid immune recognition. 
 
2.  VIRION STRUCTURE 
 
The virion of HCMV consists of a 100-nm diameter icosahedral nucleocapsid containing a 
230-kbp, double-stranded linear DNA genome surrounded by proteinaceous layer defined 
as the tegument or matrix, which, in turn, is enclosed by a lipid bilayer containing a large 
number of viral glycoproteins (Fig. 1). The mature virion particle is 150-200 nm in 
diameter. The viral genome in the characterized cytomegaloviruses is a linear DNA 
ranging in size from 200-240 kbp which is significantly larger than other herpesviruses 
and the human CMV genome exhibits a pattern of terminal and inverted repeats that vary 
in size in various strains. 
HCMV-infected cell cultures produce the infectious virions and another two types of 
morphological particles: non-infectious enveloped particles (NIEP) and dense bodies 
(DB). 
NIEPs are defective viral particles composed of enveloped immature capsides (type B) 
that lack DNA, but contain the viral scaffolding/assembly protein (AP) normally absent 
from fully mature nucleocapsids (C-capsids). DBs are enveloped particles that lacks an 
assembled n ucleocapsid and viral DNA, but contain several tegument proteins of which 
ppUL83 (pp65 or lower matrix protein) is the most abundant. The relative amounts of the 
three forms depends on the number of passages in cell culture and the viral strain.  . 
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FIGURE 1. HCMV structure. HCMV virions comprise three major layers. The first layer is the 
nucleocapsid containing the double stranded viral DNA genome, which is surrounded bt a proteinaceous 
tegument layer. The tegumented capsids are enveloped by a host-derived lipid bi-layer that is studded with 
viral glycoproteins 
 
 
 
2.1 Structural proteins of the virion 
 
The proteome of the HCMV is extraordinarily complex and encodes a spectrum of 
proteins that include regulatory proteins , virion structural proteins, proteins that facilitate 
evasion of the host innate and adaptive immune responses, and proteins that modulate host 
cell transcription. 
The HCMV virion has been structurally divided into three regions: the capsid , tegument, 
and the envelope. 
Capsid protein. The capsid is the innermost structure of the virion; is a icosahedral 
structure consisting of 12 pentons, 150 hexons, and 320 triplexes[1, 2]. The protein 
components of the capsid include at least five proteins: UL86 (the major capsid protein, 
MCP), UL48-49 (the smallest capsid protein, SCP), UL85 (minor capsid protein, mCP), 
UL46 (minor capsid binding protein), and fragment of UL80 (assembly protein) [1, 3, 4, 
5, 2, 6]. Through protein interactions and the scaffolding activity of the uncleaved UL80, 
these proteins self- assemble into an icosahedral structure that incorporates unit length 
viral DNA [1, 7, 2, 6]. The major capsid protein, pUL86, is the most abundant protein 
component of the capsid (960 copies) and forms the penton and hexons of the icosahedral 
capsid [1, 2]. The minor capsid proteins, pUL85 (two copies) and the pUL46 (one copy), 
form the triplexes that are located between the pentons and hexons [1, 7, 2].    4
Tegument proteins. The virion tegument has been described as an amorphous coating of 
the capsid that maintains the association between the virion envelope and the capsid. The 
tegument appears to be formed by the sequential addition of proteins, first in the nucleus 
and then in the cytoplasm. The tegument proteins may be involved in the maturation of 
progeny virions, or may influence viral and cellular events in the early stages of infection, 
such as release of viral DNA from disassembling virus particles or the regulation of viral 
and cellular promoters. Most tegument proteins are phosphorylated and are highly 
immunogenic. Some tegument proteins are expressed in the cytoplasm (ppUL32, pp150 or 
ppUL99, pp28) or in the nucleus (ppUL69) throughout the replicative cycle of HCMV [8]. 
Others such as the tegument proteins ppUL53 and ppUL83 (pp65) are expressed in the 
nucleus of cells early after infection but late in infection are localized predominantly in 
the cytoplasm [8]. Thus it is unclear whether nuclear tegument proteins associate with the 
capsid in the nucleus or at a later step in the cytoplasmic assembly compartment [1, 2]. 
Electron microscopic studies of virion morphogenesis suggested that at least some of the 
tegument layer is acquired in the nucleus. 
The role of individual proteins in the maintenance of the structure of the virion remains to 
be determined. For example, deletion of one of the most abundant tegument proteins, 
ppUL83 (pp65), resulted in a growth modified viral phenotype that replicated in tissue 
culture [9]. Thus it is likely that many of the tegument proteins have functions unrelated to 
a structural role of the virion tegument. 
Tegument proteins that have been shown to regulate viral gene expression or modify host 
cell response to HCMV infection include ppUL82 (pp71), ppUL84, ppUL47, ppUL69, 
ppUL26 and possibly ppUL83 (pp65) [10, 11, 5, 12, 13, 14, 15]. As examples, pp71 has 
been shown to inhibit the expression of genes associated with induction of interferon 
responses. 
In addition, at least two tegument proteins are thought to be essential for the nuclear 
egress of the tegumented capsids presumably through modification of the nuclear 
cytoskeleton and nuclear membranes [16].  
The tegument protein, ppUL99 (pp28) appears to be essential for virus replication, 
perhaps by providing an essential function for virion envelopment [17, 18]. 
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2.2 Envelope glycoproteins. 
 
The virion envelopment is exceedingly complex and to date the composition of this virion 
structure is incompletely defined. Although homologs of others herpesviruses including 
gB, gH, gL, gM and gN have been identified, functional or structural homologs of α-
herpesvirus gC, gD, gE, gI or gK have not been defined in HCMV. Several of the more 
abundant HCMV glycoproteins have been shown to exist as disulfide-linked complexes 
within the virion, gCI (gB), gCII (gM/gN), and gCIII (gH, gL, gO) [19, 20, 21, 22, 23]. 
The relative abundance of the various glycoproteins is incompletely defined but recent 
studies using mass spectroscopy has suggested that glycoproteins in envelope of HCMV 
are present in the following order of abundance: gM/gN>gB>gH/gL/gO [24]. To date, gB, 
gM/gN, and gH have been shown to be essential for the production of infectious virus 
[25].  
Glycoprotein B. Several structural and antigenic features if HCMV glycoprotein B (gB) 
are conserved in other CMVs [26, 27, 28]. The mature gB is a type I membrane 
glycoprotein consisting of 110-116 kDa ectodomain or surface component linked by 
disulfide bonds to a 55 kDa transmembrane component. Together these are linked through 
interchain disulfide bonds to form the mature homodimer [29, 30]. The gB is extensively 
glycosylated and contains approximately 50-60 kDa of N-linked sugars and at least one O-
linked carbohydrate modification [31]. Others posttranslational modifications of gB 
include the phosphorylation of serine at amino acid position 900, a modification that has 
been shown to be responsible for the interaction of this glycoprotein with components of 
the endosomal recycling system, including PACS-1 (phosphofurin acidic cluster sorting 
protein-1) [32, 33, 34, 35, 36].  gB is expressed on the membrane of infected cells and is 
incorporated in the virions during the envelopment process in different subcellular 
compartments. 
gB is highly immunogenic and is the major target of neutralizing immune response. gB 
specific neutralizing antibodies are able to inhibit the attachment of virions to the cellular 
surface. 
Glycoprotein H, L, O. The gCIII complex of glycoproteins was originally thought to 
consist of glycoprotein H (gH) and glycoprotein L (gL) based on studies of  α-
herpesviruses. Studies from at least two laboratories definied a third component of the 
complex, a viral glycoprotein that was subsequently shown to be encoded by the ORF 
UL74 (gO) [37, 38, 39]. Homologs of gO have been described in Epstein-Barr virus and   6
HHV-6, although in this later case this glycoprotein has been termed gQ. The HCMV gO 
is highly glycosylated membrane glycoprotein with a cleavable signal sequence [40, 41]. 
Recent studies have indicated that deletion of the gO gene does not prevent the assembly 
and release of infectious virus, although the mutant virus appears growth impaired [25]. 
One of the most striking results from studies of gO is the variation of the nucleotide 
sequence  in the 5’ end of the UL74 gene [42, 43]. It is of interest that the gO gene is 
adjacent to UL73 ORF which encodes gN, a viral glycoprotein that also exhibits 
significant amino acid and nucleotide variation between viral strains. 
Similar to the gH of others herpesviruses, HCMV gH requires coexpression of gL for 
intracellular transport and terminal carbohydrate modifications [44]. HCMV gL remains 
localized in the endoplasmic reticulum (ER) when expressed in the absence of gH. 
Because gO is not required for the production of infectious virus in vitro, it also unclear 
whether it is required for transport of the gH/gL complex to the assembly compartment or 
if authentic glycosylation of gH  and gL require the expression of gO. The gH of HCMV 
is the target of virus-neutralizing antibodies and these antibodies appear to function by 
blocking a post attachment event such as membrane fusion or virus penetration [45, 46]. 
Although anti-gH monoclonal antibodies appear broadly reactive, HCMV can modulate 
gH expression to evade virus neutralization, a phenomena similar to that reported for 
pseudorabies virus [39, 47]. The incorporation of gH into the envelope of infectious virus 
has been shown to be variable and, under antibody selection, infectious virion containing 
limiting amounts of gH could be selected [39]. This finding suggested that the 
stoicheiometry of the envelope glycoproteins that are required for production of infectious 
particles is variable and assembly of the virion envelope is considerably less structurally 
constrained as compared with the more highly ordered capsid. 
Glycoprotein M, N. The predicted structure of HCMV glycoprotein M (gM) includes 
seven membrane spanning domains, structure that appears relatively conserved among 
gMs of α-,  β-,  γ-herpesviruses [48]. The HCMV gM contains a single N-linked 
carbohydrate modification [23]. Although the structure of gM remains undefined, an 
obvious structural requirement for gM is complex formation with the product of the UL73 
orf, gN [23]. This complex forms in the ER and is dependent on both covalent disulfide 
bonds and noncovalent interactions [23]. Native folding and intracellular transport of both 
gM and gN require complex formation [23]. Infectious virus cannot be recovered from 
viral genomes  with deletion in either the UL100 or UL73 gene [25]. This in contrast to 
findings in the α-herpesvirus and pseudorabies virus in which deletion of gM was not   7
associated with loss of infectivity unless additional genes encoding glycoprotein E and 
glycoprotein I were also deleted [49]. This suggests that requirements for glycoprotein 
function may vary considerably between different herpesviruses. 
The HCMV gN is unique in its structure and its sequence variability [50, 23, 51]. The 
UL73 orf encodes a 129 amino acid polypeptide with a signal sequence and a single C-
terminal hydrophobic domain typical of a type I glycoprotein. The mature gN (complexed 
with gM) has an estimated molecular mass of nearly 60 kDa  and glycosidase treatment 
indicates that approximately 40 kDa of the mass of the mature gN is carbohydrate [23]. 
These modifications are almost exclusively O-linked sugars, a finding consistent with the 
predicted serine/threonine  content of the primary sequence. The role this posttranslational 
modification of gN plays in the biology of the HCMV is unknown, but it is of interest that 
the total number of sites for O-linked carbohydrate modification is relatively conserved 
regardless of the amino acid sequence variation in the ectodomain of gN. The second 
unique characteristic of gN is the variability in the predicted amino acid sequence of the 
gNs from different clinical viral isolates [50, 51]. In some cases, gNs from clinical isolates 
have up to 20% amino acid variability in the approximate 100 amino acid ectodomain, 
whereas the primary sequence of the short cytoplasmic tail of the gN molecule is 
conserved. Pignatelli and coworkers have analyzed the sequence from more than 200 
HCMV isolates and grouped gNs into four major genotypes, with two genotypes further 
segregating into additional subgroups [52]. Sequence  analysis suggested that variations in 
the ectodomain of gN resulted from positive selective pressure such as would be observed 
with a virus neutralizing antibody response [52]. The finding that gN in virions is possibly 
under positive immune selective pressure could argue that extensive carbohydrate 
modifications serve to shield the gN from antibody recognition similar to that which has 
been observed for HIV gp120 [53].  
HCMV-specific glycoproteins. In addition to these well-described glycoproteins, the 
envelope of HCMV has also been shown to contain several glycoproteins that do not have 
obvious homologous proteins in other herpesviruses. These include gpTRL10, gpTRL11 
and gpUL132 [54, 55, 56]. Deletion of gpTRL10 and gpUL132 have no effect on 
assembly of infectious virus, although the phenotype of these viruses remains 
incompletely characterized [57, 56].  
the product of the TRL11 orf  has been shown to have Fc binding activity and may 
responsible for the Fcγ receptor activity observed in infected cells [54].    8
Glycoproteins encoded by genes within the US region (US2-11) have been shown to have 
dramatic effects on the expression of major histocompatibilily complex class I and II 
antigens and thus have been most well studied as immune evasion gene products 
expressed in infected cells [58]. Convincing evidence of their presence in the envelope of 
infectious virus has not been presented. Recent studies have suggested that the chemokine 
receptor homologs encoded by US28, US27, and UL33 may be incorporated into the 
particle; however, it is unknown whether they are in the envelope [59, 60].  
Additional glycoproteins such as that encoded by the UL4 orf (gp48) has been suggested 
to be components of the infectious virus, but they localization to the envelope has not 
been confirmed [61].   
It is almost assured that additional HCMV specific glycoproteins will be found in the 
envelope of the infectious virion. Even if these proteins are shown to be nonessential for 
in vitro replication of HCMV, it is presumed that they have a role in the in vivo replication 
and spread of HCMV.  
 
 
3.  VIRUS GENOME 
 
The HCMV genome is the largest of all herpesviruses and has a high G+C content. Like 
that of herpes simplex virus-1, it contains an arrangement of unique long (UL), unique 
short (US), and repeat regions (Fig. 2). Since each long and short region can be oriented in 
either direction, four genomes isomers are produced in viral progeny (Class E structure). 
In contrast, the genome of animal CMV, as well as those of other betaherpesviruses, are 
linear without repeat regions (Class F genomes). Inversion of UL and US regions is 
mediated by direct repeat sequences (a, b,  c) at the genome termini and by inverted repeat 
elements at the UL-US junction  (a’, b’,  c’). the repeated a sequence that occurs as a 
direct element at the termini and in the inverted orientation at the UL/US junction 
promotes genome isomerisation, since it contains the cis-acting pac (packaging) elements 
needed for DNA cleavage. 
 
   9
             
 
 
 
 
 
The AD169 laboratory strain is the only completely sequenced HCMV. Analysis of its 
230-kbp genome has revealed that it encodes 255 ORF of ~ 100 or more amino acids [62, 
63]. These ORFs are designated sequentially according to their location within the unique 
and repeated regions. Additional ORFs have been identified in the Towne and Toledo 
laboratory strains. In latter, as well as in clinical isolates, the inverted b’ repeat is deleted 
and replaced by additional UL region of ~ 15 Kbp, containing 19 additional ORFs that are 
absent in the Ad169 genome [62]. The unique ORF UL1-154 and US1-36 blocks are 
separated by duplicated IRL1-14 and J1I genes and the partially repeated IRS1 gene. The 
UL region is flanked at the 5’  end by the duplicated TRL1-14 and J1L (identical to IRL1-
14 and J1I), whereas the US gene block is flanked at its 3’ end by the TRS1 gene and by 
the third copy of a J1 gene (J1S). 
 Sequence homology searches and experimental biochemical and/or genetic studies have 
assigned functional roles to only some of the more then 200 HCMV ORFs [63]. However, 
analysis of the phenotypes of spontaneous deletion mutants of the AD169 strain, as well 
as those of virus-bearing deletions or inactivation at specific loci, has indicated the 
products of more the 50 HCMV ORFs are dispensable for productive replication in 
FIGURE 2. Schematic rapresentation of herpesviruses genomes. 
HSV: herpes simplex virus; VZV: varicella zoster virus; CMV: cytomegalovirus; EBV: 
Epstein Barr virus   10
fibroblast cultures. These findings, along with observations that the proteins responsible 
for functions common to all herpesviruses, such as basic DNA replication, virion 
organization, and maturation, do not account for all the ORFs, indicate likely, therefore, 
that much of the coding capability has evolved to optimize infection by influencing 
dissemination, growth in target tissues and pathogenesis, and in counteracting host 
immune reactivity.  
 
 
4.  VIRUS GROWTH CYCLE AND VIRAL GENE EXPRESSION 
 
4.1 Initial steps of HCMV infection: virus binding and penetration 
 
HCMV causes systemic infection and exhibits a tropism for fibroblasts, endothelial cells, 
epithelial cells, monocyte/macrophages, smooth muscle cells, stromal cells, neuronal 
cells, neutrophils and hepatocytes [64, 65, 66]. This exceptionally broad cellular tropism 
is the root of HCMV disease manifestation of most organ systems and tissue types in the 
immunocompromised host. Although HCMV is considered to have a very restricted cell 
tropism in vitro, entry into target cells is very promiscuous, as HCMV is able to bind, fuse 
and initiate replication in all tested vertebrate cell types. Productive in vitro replication is 
only supported by primary fibroblasts, endothelial cells and differentiated myeloid cells as 
well as certain astrocyte cell lines [64, 67].  
Virus attachment and penetration are rapid and efficient in both permissive and non 
permissive cell types. However, since productive replication is observed in a very 
restricted range of human cells, a post-penetration block to viral gene expression is 
thought to restrict replication in non permissive cells [66]. 
The ability of HCMV to enter such a wide range of cells is highly indicative of multiple 
cell specific receptors, broadly expressed receptors or a complex entry pathway in which a 
combination of both cell specific and broadly expressed cellular receptors are  utilized. 
Viral entry is the result of a cascade of interactions between viral and cellular proteins that 
culminate in fusion of the virion envelope with the cellular plasma membrane by a PH-
inde pendent mechanism. 
The initial events in the replication cycle are only partially understood. 
It has been known for some time that HCMV initiates infection via a tethering interaction 
of virions and cell-surface heparan sulphate proteoglycans (HSPGs) [68]. At least in cell   11
culture system, HCMV engagement of HSPGs is thought to play a crucial role in 
recruiting virions to the cell surface and enhancing the engagement of others receptors. 
HCMV virions were initially shown to bind β2 microglobulin (β2m) [69]. This 
observation led to numerous binding studies concluding that HCMV tegument binds β2m 
as it is released from cells. This  β2m-HCMV complex was then thought to associate with 
alpha chain of HLA class I antigens [70, 71, 60] However, it was later determined that 
β2m expression had no  correlation with in vitro entry or in vivo spread of infectivity [71, 
72, 73]. Virus-cell overlay blots were used to globally analyze cellular proteins that could 
bind to HCMV virions. These studies identified a cell-surface protein of approximately 30 
kDa, whose expression correlated with cells permissive for entry [67, 74]. This protein 
was later identified as annexin II [75]. Annexin II was also shown to bind HCMV virions 
[75, 76]. Upon further study it was found that gB was able to directly interact with 
annexin II and that this protein was able to enhance HCMV binding and fusion to 
phospholipid membranes [77, 78]. However, cells devoid of annexin II are fully 
permissive for entry and initiation of infection [79]. What role, if any, annexin II  plays in 
the life cycle of HCMV is unknown but, given its membrane-bridging activity, it remains 
formally possible that this enhances entry, cell-cell spread and/or maturation and egress.  
CD13, or human aminopeptidase N, has also been implicated as a HCMV receptor. This 
hypothesis was based on that fact that only human peripheral blood mononuclear cells 
(PBMCs) that were CD13 positive supported productive infection [80, 34]. 
A consideration of HCMV-induced signalling cascades led Wang et al.(2003) to 
hypothesize a role for epidermal growth factor receptor (EGFR) as an HCMV receptor. A 
limitation of  the study, however, was that there was no experimental evidence that EGFR 
functioned in a entry event per se. Nor was it shown if EGFR was required for the 
delivery of virion components across the plasma membrane. Lastly, is important to note 
that EGFR is not expressed on all HCMV permissive cells, including those of 
haematopoietic lineage. 
 
Cellular integrins  may serve as co-receptors for cytomegalovirus. The first and foremost 
observation about HCMV biology was its namesake characteristic, cytomegaly, or cell 
enlargement. In vitro studies initially demonstrated a unique cytopathogenic effect (CPE) 
of infected cells, with HCMV-infected cells appearing round and enlarged with 
intracellular viral inclusion bodies [81]. The cause of this phenomenon was widely 
speculated upon; theories for HCMV-induced cell rounding included cation influx,   12
suppression of fibronectin synthesis and integrin down-regulation [82, 81, 83, 84, 85] 
have tested the hypothesis that integrins were involved in the HCMV entry pathway.   
(Fig. 3) 
 
 
        
                      
 
FIGURE 3. Working model for HCMV entry into cells. 
 
 
 
 
Attachment to the cell surface is followed by penetration, mediated by fusion of the virion 
envelope and the cell surface in a pH-independent manner. 
However, final fusion of the viral envelope with the cell membrane to allow viral 
penetration is thought to require a further priming event mediated by the heteroligomeric 
gH-gL-gO complex with as yet unidentified receptors. Fusion of the virus and cell 
membranes is followed by entry into the host cytoplasm of the nucleocapsid and tegument 
proteins, and their rapid translocation into the nucleus, where pp65 is detected < 1 hr p.i. 
and expression of IE1/IE2 products follows shortly thereafter. Several studies have shown 
Interaction  of HCMV glycoproteins with their receptors is  enough to generate an 
intracellular signal transduction  pathway, leading to the alteration of cellular gene 
expression. Viral attachment may therefore stimulate specific cellular processes that 
facilitate viral replication. 
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4.2 Regulation of viral gene expression 
 
During productive infection, the HCMV genome is expressed in a temporally coordinated 
and regulated cascade of transcriptional events that lead to the synthesis of three 
categories of viral proteins described as immediate-early (IE or α ), early (E or β), and late 
(L or γ). Failure in the expression of early gene and subsequent viral DNA replication 
rather than attachment and/or penetration may be the 
restricting event in non permissive cells. HCMV genes are transcribed in the infected cell 
nucleus by RNA polymerase II and the associated basal transcription machinery, with the 
intervention of host-encoded transcription factors whose activity may be stimulated by 
viral transactivators. 
 
4.2.1 Characteristics and functions of the immediate-early proteins 
 
HCMV gene expression initiates from a few IE proteins within l hr p.i. without de novo 
protein synthesis. The IE genes include the major IE (MIE) UL122/123 genes (IE1 and 
IE2) and auxiliary genes, such as UL36–UL38, UL115–UL119, IRS1/TRS1, and US3. 
The MIE proteins, alone or in synergism, are required for subsequent expression by acting 
as transactivators and autostimulators of viral genes. In addition, these proteins have a 
deep impact on host cell physiology since they regulate the expression of 
a large number of host cell genes.  MIE proteins are encoded by the ie1/ie2 genes 
(UL122/UL123), whose expression is regulated by a complex  enhancer-modulator 
element that functions in a tissue- and cell-type-specific manner, and exerts its strong 
transcriptional activity through interactions with several host transcription factors whose 
binding sites are closely distributed within the regulatory element. 
 
4.2.2 Characteristics and functions of the early proteins 
 
Expression of E or β genes depends on the presence of functional IE proteins and is 
unaffected by inhibitors of viral DNA replication. They are divided into two subclasses: 
β1 (E) and β2 (E-L) according to their time of expression. β1 genes are transcribed within 
4–8 hr p.i., β2 transcription 8–24 hr p.i.. The functional data indicate that E genes encode 
mostly non-structural proteins, including viral DNA replication factors, repair enzymes, 
and proteins involved in immune evasion. The expression profiles of microarrays of viral   14
DNA recently have provided a temporal map of IE, E, and L genes in the entire viral 
genome. Hybridization of such microarrays to cDNAs prepared from 
HCMV-infected cells treated with ganciclovir (GCV) to block viral DNA replication has 
revealed that 36% of the more than 150 ORFs scored positive for expression were 
unaffected by GCV and, therefore, classified as E. These E genes are dispersed throughout 
the HCMV genome.  
 
4.2.3 Characteristics and functions of the late proteins  
 
The L proteins are the last class of gene products expressed during HCMV replication. 
Their transcription begins more than 24 hr p.i. and requires prior viral DNA replication. 
Late or γ gene expression leads to the synthesis of two subclasses of L proteins (γ1 and 
γ2) in accordance with their time of expression and sensitivity to viral DNA replication 
inhibitors.  γ1 (leaky late) transcription occurs 24–36 hr p.i., and is reduced by such 
inhibitors. γ2 (true late) transcription occurs 24–48 hr p.i., and is strictly dependent on 
DNA replication. The L proteins have mainly structural roles and primarily contribute to 
the assembly and morphogenesis of the virion.  
 
 
4.3 Virion Morphogenesis 
 
Formation of HCMV capsids and packaging of viral DNA occur in the nucleus. 
Assembled cytomegalovirus nucleocapsids are exported from the nuclear compartment by 
sequential events including (i) primary envelopment at the inner nuclear membrane and 
(ii) de-envelopment at the outer nuclear membrane prior to (iii) secondary envelopment of 
naked cytoplasmic nucleocapsids at cytoplasmic cisternae, and (iv) release of mature 
enveloped particles by exocytosis. [86] and later Severi et al. (1979) deduced from 
electron microscopic studies that acquisition of an envelope derived from the inner 
nuclear membrane (INM) (primary envelopment) was only temporary.  
Regarding viral exit, budding of nucleocapsids at the INM leading to primary 
envelopment produces vesicular (temporarily enveloped) structures in the perinuclear 
space that are normally not seen in uninfected cells. The temporary envelope is lost by de-
enevelopment at the outer nuclear membrane (ONM) which is contiguous with the rough 
endoplasmic reticulum (RER).    15
Final maturation occurs by a secondary budding process (secondary envelopment) of 
naked unenveloped nucleocapsids at cytoplasmic vesicles thereby acquiring an envelope 
with processed membrane proteins. These transport vesicles are targeted to the plasma 
membrane which fuses with the vesicle membrane and enveloped mature viral particles 
are exocytosed into the extracellular space. 
There are still controversial views regarding the definition of the cellular compartment of 
secondary envelopmnent. Clearly, the cellular membranes are enriched by viral envelope 
proteins whose cytoplasmic domains evidently interact with cellular factors [87] and may 
modify the compartmental properties.   
 
It generally accepted that viral transmembrane glycoproteins are subject not only to 
anterograde transport along the cellular exocytosis pathway to plasma membrane from 
where they are retrieved to the cytoplasmic compartment of final viral maturation but also 
to a retrograde transport from the site of biosynthesis, namely the rough endoplasmic 
reticulum (RER), into the inner nuclear membrane presumably by lateral diffusion [5, 88, 
89]. Presence in the INM has been demonstrated  for the conserved glycoproteins B and H 
(gB and gH; [55, 90]. 
There is genetic and biochemical evidence from the herpes simplex virus (HSV) that two 
conserved  viral proteins, UL31 and UL34, are essential for viral exit from the nucleus. 
Transient coexpression of these viral gene products results in colocalizaton at the nuclear 
envelope [91, 92]. There evidence from recent reports that the recombinant UL34 product 
not only induces morphological alterations of the nuclear envelope similar to those in 
infected cells [34] but that the UL34/UL31 complex also triggers modifications of the 
nuclear lamina, possibly by direct interaction with lamin A/C [93]. Only limited 
information is presently available for the counterparts of HCMV, UL50 and UL53. 
Interestingly, pUL50 was found in the INM following solitary expression and 
morphological changes were comparable to those in cells cotransfected with M50/p35 and 
M53/p38 [16]. On the other hand, when transfected alone pUL53 exhibited diffuse nuclear 
distribution but colocalize with lamin B in punctuate patches along the nuclear periphery 
in HCMV-infected cells [94].   
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5. PATHOGENESIS 
 
The pathogenesis of infections with human cytomegalovirus have modelled in small 
animals and primates utilizing the respective CMVs. In most cases, acute infection is 
associated with significant levels of virus replication and dissemination to multiple organs. 
In the immunocompetent animal, such infections are rapidly controlled by a number of 
effectors functions of the innate and adaptive immune response. The pathogenesis of acute 
HCMV infections can be readily explained by the control of virus replication and the 
resolution of virus-induced cytopathology. There appears to be a linkage between levels of 
virus replication, organ dysfunction, and disease in patients as well as in experimental 
models with acute CMV infections. In contrast, chronic infections with CMV have as a 
major component of their pathogenesis a bidirectional relationship between viral gene 
expression and the host inflammatory response such that viral persistence is facilitated by 
the host inflammatory response and the host inflammatory response is fuelled by the 
presence of the virus. In these cases, diseases can be attributed to both viral and host 
functions. The viral gene products that appear to play a role in chronic inflammation have 
evolved with CMVs and are likely  unimportant for replication in vitro. As such, defining 
the role of these viral functions in disease associated with chronic HCMV infections almost 
certainly will require relevant animal models. 
 
 
 
5.1 Immunity 
 
HCMV infections are kept under control by the immune system. Histopathologic and 
immunohistochemical examination of necropsy tissues has indicated that the virus initially 
enters via the epithelium of the upper alimentary, respiratory, or genitourinary tracts. 
However, since infection is readily established by transfusion and transplantation, initial 
infection of epithelial cells does not seem essential [95]. Cytotrophoblasts form a barrier 
between the maternal and fetal circulation, but readily allow HCMV replication in vitro, 
suggesting that the fetus is infected hematogenously [2, 96]. Leukocytes and vascular 
endothelial cells aid the spread of HCMV, however, is rarely achieved, and the viral 
genome remains at selected sites in a latent state. Initiation of productive replication 
results in transient virus shedding and recrudescent disease [97]. Since severe infection is 
usually restricted to individuals with impaired cell-mediated immunity, it is evident that 
this arm of the immune response provides the most protection. Even so, the supportive   17
role of the humoral system in keeping CMV loads below critical thresholds must not be 
overlooked. 
 
5.1.1 Cell-Mediated Immunity 
 
Mouse models have been employed to determine the role of specific components of the 
immune response and their recognition of viral proteins [98]. Early studies demonstrated 
that a CMV-specific cytotoxic T lymphocyte (CTL) response was required for recovery 
from CMV infection. Suppression of CTLs caused reactivation and dissemination of 
natural infection. Further studies showed that both natural killer (NK) cells and CD8+ 
cytotoxic T-cells are of primary importance in the prevention of recurrence [99, 100, 72]. 
Adoptive transfer of CD8+ cells protected mice from lethal challenge independent of 
CD4+ T helper cells. CD8+ T-cell clones specific for both structural and non structural 
proteins were identified. However, CD8+ depletion with abs or in mouse mutants 
deficient in MHC Class I expression revealed additional antiviral activities mediated by 
CD4+-derived cytokines not seen when CD8+ cells are present. Lastly, experiments with 
mice deficient for perforin and granzyme- or Fas-mediated cytotoxicity have shown that 
replication is controlled by NK and CD8+ cells via the perforin and granzyme-mediated 
pathway, 
whereas the Fas-Fas ligand system is not critical [101, 102]. Since infection (apart from 
congenital forms) is most severe in patients with  dramatically impaired cell-mediated 
immunity, such as BMT recipients, and those with AIDS, it is evident that this arm of the 
immune response provides the most protection [103]. Its investigation in studies of 
lymphocyte proliferation in response to CMV antigens has shown that in most 
seropositive immunocompetent adults, this usually takes the form of CD4+ cell 
proliferation in response to envelope glycoproteins gB and gH, the lower matrix protein 
pp65, and IE proteins, in addition to other proteins  [26, 10, 104]. The function of 
proliferating CD4+ cells in resistance to HCMV infection is not clear. Studies in mice 
point to several antiviral effector functions, such as the production of cytokines and 
CD4+- 
mediated cytotoxicity. The virus-encoded proteins that are targets of CTLs include a 
collection of structural and non-structural forms [105, 106]. Comparison of CTL precursor 
frequencies for envelope gB or the 72-kDa IE1 protein revealed a low frequency of gB 
specific CTLs ( < 6%), whereas 18–58% of CTLs recognized IE1-expressing target cells.   18
The high frequencies for pp65 and IE1 proteins found in subsequent studies show that 
they are the chief targets of the CTL-mediated immune 
response. Although a direct role for virus-specific CTL responses in the resolution of 
infection has yet to be defined, in vivo evidence of the control of HCMV infection by 
CTLs has been obtained through the adoptive transfer of virus-specific clones. Passive 
administration of autologous HCMVspecific CD8+ CTLs at set intervals after BMT to 
seronegative recipients of marrow from seropositive donors generated a vigorous CMV-
specific CTL response without 
onset of viremia or CMV disease [107]. These studies provided the first evidence for the 
role of CTLs in controlling human CMV infection, and opened new therapeutic 
perspectives for CMV treatment in organ transplantation. 
 
5.1.2 Humoral Immunity 
 
During primary infection, immunocompetent individuals produce anti-HCMV 
immunoglobulin (Ig)M class abs that persist for 3–4 months, followed a few weeks later 
by IgG class abs that persist for life. Experimental and clinical findings show that the 
humoral response is beneficial. 
Mice immunized against murine CMV gB were protected against a lethal challenge , and 
immunization of pregnant guinea pigs against guinea pig CMV envelope glycoprotein 
protected their fetuses in the same way [108]. Intrauterine infection is less severe when 
transmitted by means of recurrent rather than primary maternal infection . During primary 
infection, women who transmit the virus in utero have high levels of total IgG 
characterized by low avidity and neutralizing activity. Correlation of an enhanced 
antibody response with a poor fetal prognosis suggests that fetal antibody is responsible 
for immunopathology. Primary infection is more frequent and more severe when the renal 
transplant recipient is seronegative and the donor seropositive. Alleviation of this severity 
by preimmunization with the attenuated Towne strain [109] or administration of high-titer 
anti-CMV Igs [110] also shows that humoral immunity is beneficial. Many CMV proteins 
are recognized by the humoral immune system [111, 112]. The envelope glycoproteins 
(mainly gB and gH) are the targets of virus-neutralizing abs in both human and mouse 
models. The predominance of gB as a target is best explained by its dominant 
immunogenicity and abundance compared with other components of the envelope. Anti-
gH abs have a potent, complement-independent, but minor neutralizing activity. Viral   19
tegument components, including pp28 (UL99), pp65 (UL83), and pp150 (UL32), trigger 
an intense and long-lasting ab response that provides an indirect measure of viral 
replication and correlates with the clinical outcome. However, these abs are  
unable to react with the surface of virions and infected cells, and are of limited importance 
in a protective response. 
 
5.2 Immune evasion by Human Cytomegalovirus 
 
A characteristic feature of infection in the normal host is persistence of the viral genome 
in a nonproductive form at specific anatomical sites for months or even years [99]. This 
ability to avoid elimination by the immune system is the result of (i) induction of a latent 
state of infection, (ii) exploitation of immunologically privileged tissues for replication 
(i.e., epithelial cells of the salivary glands expressing an insufficient number of MHC 
Class I molecules to trigger clearance by CD8+ cell, and (iii) expression of genes that 
interfere with the immune response [113]. Escape from CD8+ cells is mediated by several 
mechanisms, all of which block the expression of MHC Class I molecules complexed with 
a potentially important CTL target, the 72-kDa IE1 phosphoprotein, or which degrade 
MHC Class II molecule proteins, and, thus, prevent presentation of viral antigen to CD4+ 
lymphocytes. 
HCMV deletion mutants have been used to map two gene regions whose products are 
associated with the downregulation of MHC Class I complex formation; namely, US11 
and that spanning US2 and US5 [114]. Both US2- and US11-encoded proteins lead to the 
accumulation of MHC Class I heavy chains in the cytosol of infected cells, where they are 
degraded by the proteosome, thus shortening their half-life and preventing their 
expression on the cell surface. Binding of peptides to MHC Class I molecules depends on 
transport across the ER membrane by a specific transporter complex designated TAP 1/2 
(transporter associated with antigen processing). Only after their introduction into the ER 
can peptides form heterodimers with MHC Class I molecules and b2-microglobulin and 
be recognized by CD8+ CTLs. Despite a significant increase in the expression of TAP 
molecules in infected cells, the HCMV glycoprotein encoded by the US6 gene inactivates 
the TAP system by interfering with formation of the TAP1- TAP2-MHC Class I-b2-
microglobulin complex. The finding that lysis of HCMV-infected fibroblasts by IE-
specific CTL is usually low, but increases in fibroblasts infected with a mutant HCMV 
lacking the UL83 encoding the matrix pp65, suggests that phosphorylation of the 72-kDa   20
IE1 protein by pp65 interferes with its antigenic processing and presentation to CD8+ 
cells [5, 115, 116]. Experiments have demonstrated that NK cells are involved in the 
control of CMV infection. Beige mice (genetically deficient in functional NK cells) are 
more susceptible to murine CMV [117]. In humans, MHC Class I HLA–E molecules 
protect target cells from NK cells by binding to inhibitory receptors on their surface. A 
convincing mechanism for escape from NK cell attack stems from the observation that the 
HCMV UL40 gene encodes for a glycoprotein containing a nine amino acid sequence 
homologous to the MHC Class I sequence that up-regulates the expression of Class I 
HLA-E molecules [118]. Lastly, mechanisms interfering with chemokine-driven 
inflammation are exploited by HCMV to evade the immune response. HCMV-infected 
cells express viral G-proteincoupled 
receptor (GPCR) homologues encoded by US27, US28, UL33, and UL78, which are 
needed for virus replication in vitro [119, 62]. The US28-encoded GPCR binds to and 
sequesters several b-chemokines and, thus, enables the virus to evade the immune 
response. 
 
5.3 Persistence and release from the host 
 
Cells in bone marrow and peripheral blood are the chief reservoirs for latent CMV 
infection. CMV DNA is found in a small percentage of peripheral blood monocytes, and 
gene expression is limited to the E genes. These findings and the demonstration that tissue 
macrophages differentiated from circulating monocytes also express E and L genes have 
led to the formulation of the following model: bone marrow precursors of blood 
monocytes are the site of 
CMV latency and provide a means of dissemination upon differentiation into circulating 
monocytes. Differentiation of latently infected monocytes into macrophages leads to 
reactivation and productive infection. Support for this model is provided by the 
reactivation of CMV by allogeneic stimulation in vitro of peripheral blood mononuclear 
cells from seropositive healthy donors [34]. Moreover, it has been found that a small 
percentage (close to 0.01%) of CD33+/CD14+ or CD33+/CD15+ bone marrow 
mononuclear cells from seropositive human donors express transcripts associated with 
latency. In contrast, T lymphocytes, B lymphocytes, and CD33- mature granulocytes and 
macrophages are negative  [120].   21
Recurrent infection can be defined as indefinite, but intermittent, excretion of the virus 
from single or multiple sites. It should be distinguished from the prolonged excretion 
typical of primary infection and also infection in the immunocompromised host, where 
productive infection, as measured by viral excretion, is markedly increased. In allograft 
recipients and AIDS patients, the incidence of virus excretion from multiple sites 
approaches 100%. During primary, recurrent, or persistent infection, CMV is shed in 
multiple body fluids, such as saliva, urine, tears, cervicovaginal fluid, breast milk, and 
semen, probably due to virus replication in glandular epithelial cells, accompanied by 
virus release into excretions. 
 
 
6. EPIDEMIOLOGY OF HUMAN CYTOMEGALOVIRUS INFECTION 
 
Epidemiology of human cytomegalovirus infection HCMV is one of the most successful 
parasites. It is found in both the developed industrial societies and in isolated aboriginal 
groups. Following infection, it is excreted in body fluids (urine, saliva, tears, semen, milk, 
and cervical secretions) for months to years. Infection is usually mild and subclinical. The 
unsuspecting host is thus able to spread the virus both vertically and horizontally. Virus 
can appear following primary infection, reinfection, or reactivation. 
Infection is life long. Latent CMV may reactivate and produce infectious virions that are 
shed in the saliva, urine, and other body fluids. Reactivation is usually asymptomatic, and 
enables the virus to spread horizontally and vertically.   
 
Congenital infections  
About 10% of infants are infected by the age of 6 months, following transmission from 
their mothers via the placenta, during delivery, and by breast feeding  [121, 122]. 
Transplacental infection can occur both in women infected for the first time during 
pregnancy and those infected long before conception (recurrent infection). Primary 
infection during pregnancy as a source of fetal infection was suggested by the observation 
that transplacental transmission ranges from 20% to 40% when primary infection varies 
from 0.7% to 4.1% [123]. In the case of recurrent infections, high rates of congenital 
infections are observed in populations with higher rates of maternal seropositivity, 
suggesting that most congenital infections are caused by reactivation of latent virus [124, 
125]. Breast-feeding is the most common route of transmission. Polymerase chain reaction   22
(PCR) studies have also demonstrated a strong relationship between the presence of viral 
DNA in milk and transmission to the infant. The precise route of infection throughout 
childhood is not known, although close contact is required. Infection increases when 
people live in crowded, unhygienic conditions, and hence is most common in socially 
disadvantaged countries. The incidence of congenital infection is highest in poor 
communities, since most women are infected before puberty. Reactivation is thus a more 
frequent cause of congenital infection than primary maternal infection, although the latter 
presents a greater risk to the fetus than recurrent infection.  
Primary infection does not usually result in a clinical illness, and cannot be identified in 
pregnant women. Its status as a risk factor for fetus infection is thus uncertain. Intrauterine 
infection occurs in only one-third of pregnant women with primary infection. The ways in 
which the fetus escapes infection are unknown, although macrophages in the placenta may 
constitute a barrier.  
 
Transfusion 
Primary infection with HCMV via blood transfusions was noted in the mid-1960s, 
although epidemiologic studies have demonstrated that this is an uncommon route. 
Attempts to culture HCMV from fresh donor blood have rarely been successful. It is thus 
assumed that the virus is latent in the blood cells of healthy donors and is reactivated 
following transfusion when they encounter an allogenic stimulus. The nature of the 
leukocytes carrying latent virus is unknown, although attention is being increasingly 
focused on the monocytes/macrophages [126, 34]. 
 
Solid organ transplantation 
HCMV is a significant post-allograft pathogen. Several studies have shown that 
seronegative recipients of an organ from a seropositive donor are at risk of acquiring a 
primary infection and that 60%–80% develop a more severe disease than seropositive 
recipients of seropositive organs, suggesting that acquired immunity modulates infection 
[127, 128]. The contribution of immunity to resistance to HCMV disease, however, 
decreases as the level of immunosuppression increases. Variables that contribute to post-
transplant infection include donor and recipient serological status, type of 
immunosuppression, source of allograft, HLA matching of donor and recipient, and type 
and amount of blood products used [129, 130]. Since the main determinant of 
transmission via blood is the presence of leukocytes, reduction of the cell contamination   23
of blood products has dramatically decreased the incidence of transfusion-acquired 
infection in allograft recipients [129]. The effects of infection extend well beyond the 
immediate post-transplant period. It appears that HCMV contributes to graft loss 
independently of graft rejection. Following kidney transplantation, a histologically distinct 
glomerulopathy may result from infection of the graft and may significantly alter its 
survival  [131, 132]. The role of HCMV infection in rejection is most convincing in the 
case of cardiac allografts. Accelerated development of coronary atherosclerosis associated 
with post-transplant HCMV infection has been reported and found to be independent of 
reports of age, lipid levels, and immunosuppression regimen [133].  
 
BMT 
The incidence of HCMV infection following allogenic bone marrow transplant (BMT) 
ranges from 32% to 70%, with an average of 50%, regardless of the prior serological 
status of the recipient and donor. Typing of strains has shown that infection is due to a 
virus derived from the recipient [134, 135, 136]. Its incidence in seronegative recipients 
receiving a seropositive marrow is lower than in seropositive recipients receiving a 
seropositive marrow, suggesting a transfer of adoptive immunity from donor to recipient. 
Thus, the most critical event is reactivation of a latent virus in seropositive BMT 
recipients, whereas in seronegative recipients, transmission mostly occurs through the 
larger quantities of blood products that they receive compared with solid organ transplant 
recipients. Increasing evidence indicates that apart from the serological status of donor 
and recipient, administration of blood products carries a significant risk of exposure to 
HCMV infection following BMT. 
Another major risk factor is the immunosuppressive regimen.  
 
AIDS patients 
HCMV is a leading opportunistic agent in acquired immunodeficiency syndrome (AIDS). 
The increased survival of HIV-infected individuals following more effective prophylaxis 
and treatment of bacterial and protozoal infections, accompanied by virtual inactivity of 
their immune system, has augmented the importance of HCMV infection in these patients. 
Three major organ systems are clinically affected: the CNS, the lungs, and the 
gastrointestinal tract. Retinitis is the most frequent CNS infection directly attributable to 
HCMV replication, and the most sight-threatening [137, 138, 139, 140]. Autoptic 
immunohistochemical analysis has shown HCMV presence in all layers of the retina,   24
without underlying choroidal involvement. Absence of virus in the endothelium of the 
retinal microvasculature indicates that its hematogenous spread does not follow 
replication in these cells, but that perhaps the virus breaks through the capillary 
endothelium. 
 
 
7. MANIPULATING CYTOMEGALOVIRUS GENOMES BY BAC 
MUTAGENESIS 
 
The generation of CMV mutants has been a difficult task especially because of the large 
genome size and the slow replication cycle  of the CMVs. The recent cloning of CMV 
genomes as infectious bacterial artificial chromosome (BAC) in E. Coli opened new 
horizons for the construction of mutant CMVs by utilizing the methods of bacterial 
genetics. 
The genetic content of the AD169 strain was estimated at 145 genes and that of wild-type 
HCMV at between 164 and 167 genes. The majority of the proteins encoded by HCMV 
has not yet been characterized. Even for those proteins about which we have some 
functional knowledge, e.g. the envelope glycoproteins, a clear understanding of the mode 
of action is usually missing. A number of ORFs has been subcloned in plasmid expression 
vectors and their functions studied independently of the viral infection and separately 
from other viral genes, for istance by transient transfection experiments. However, many 
viral proteins have to interact with other viral or cellular proteins in order to exert their 
effects and many genes display a distinct temporal expression pattern during infection 
cycle. Thus, it is desirable to study the role of gens in the context of the viral infection. 
For many years the size of the CMV genomes represented an insumontable barrier, which 
prevented their cloning  as a single entity. Only the development for new cloning vectors, 
e.g. the E.Coli F-factor-derived bacterial artificial chromosome (BAC) that offered a 
cloning capacity of up to 300 kbp, made this vision become real. 
The BAC vector sequences were introduced into the viral genome by homologous 
recombination utilizing the cellular recombination machinery (Fig. 4A). to this end, 
recombination plasmid was constructed that contained the BAC vector flanked by viral 
DNA sequences homologous to the intended insertion site in the viral genome. The 
linearized recombination plasmid was transfected into fibroblasts cells followed by 
infection with the respective CMV strain [120]. recombinant viruses carrying the BAC   25
vector integrated into their genomes were amplified. Circular replication intermediates of 
the viral genomes were isolated from infected cells and electroporated into E. Coli. 
Bacterial clones harbouring CMV BACs were selected by means of the antibiotic 
resistance encoded on the vector backbone. The CMV BACs could be propagated stably 
in E. Coli [120]. Upon transfection into permissive cells, the CMV BACs gave rise to 
formation of plaques and infectious virus (Fig. 4B). the CMV BACs displayed a 
remarkable stability in E. Coli: after days or even weeks of propagation in suitable E.Coli 
hosts the BACs did not show an altered restriction profile and remained infectious. This 
property formed the basis for the targeted manipulation of the BAC-cloned CMV 
genomes in E.Coli. 
 
Mutagenesis of BAC-cloned CMV genome: ET Recombination 
 
The establishment of methods to manipulate the CMV genomes in E.Coli was the next 
step after successful BAC cloning. A mutagenesis technique uses a linear DNA fragment 
carrying a selectable marker (e.g. kanamycin resistance gene) flanked by DNA sequences 
homologous to the viral target site and to introduce the marker by two simultaneous 
recombination events, i.e. by double cross-over. (Fig. 4C). Some recombination systems 
of bacteriophages such as the recE and recT gene functions of the E.Coli prophage Rac or 
the redα and redβ functons of phage lambda utilize linear DNAsubstrates. These 
recombination proteins are highly efficient and need only 30 to 50 nucleotides of 
homologous sequences to mediate recombination. Thus, the linear recombination 
substrates can easily be generated by PCR with the homologous sequences being 
incorporated into the synthetic oligonucleotides used as primers for the amplification of 
the selectable marker . 
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MATERIALS AND METHODS 
 
Cells and Viruses. HCMV strain TR12 and recombinant viruses were propagated in primary 
human foreskin fibroblasts (HFF) grown in minimal essential medium (Invitrogen, Karlsruhe, 
Germany) supplemented with 5% fetal calf serum, glutamine (100 mg/liter), and gentamicin 
(350 mg/liter).  
To prepare intracellular particles, cells from infected cultures were trypsinized  and collected 
via low speed centrifugation. The cell pellet was subjected to three freeze-thaw cycles and 
cellular debries was removed by centrifugation at 1000 x g. supernatants were subjected to 
high speed centrifugation (23 000 rpm in a Beckmann SW27 rotor) for 70 min, the pellet was 
resuspended in medium and stored at -80°C. 
Virus titer were determined by indirect immunofluorescence using a monoclonal antibody 
(MAb) against the immediate early protein 1 (IE1) of HCMV as described. (Andreoni M. et al 
1989). 
COS7 cells were passaged in Dulbecco's modified Eagle's medium (DMEM) supplemented 
with 10% fetal calf serum, glutamine (100 mg/liter), and gentamicin (350 mg/liter). 
 
Preparation of eukaryotic expression constructs and DNA transfection 
pcTRL12myc 
The entire TRL12 reading frame was amplified from HCMV strain TR12 with the following 
primers that contain HindIII and EcoRI restriction sites, TRL12-TR-5’ (44) and TRL12-TR-
3’(45). The PCR product was cleaved with the appropriate restriction enzymes and inserted 
into the expression vector pcDNA3.1myc/His (Invitrogen, Carlsbad, Calif.). The resulting 
plasmid, pcTRL12myc/his, encoded full-length pTRL12 fused to a C-terminal Myc/His tag. 
The integrity of pcUL132myc/his was confirmed by DNA sequencing. 
pcTRL12/sig-HA  
Two different TRL12 DNA insert were PCR amplified HCMV strain TR12. The first insert 
(fragment A), encoding amino acids 33-190 of pTRL12 protein, was amplified with primers 
that contain EcoRI and XhoI restriction sites, TRL12-33-EcoRI s (82) and TRL12-570-XhoI as 
(32). 
The second insert (fragment B), encoding amino acids 191-410 of pTRL12 protein, was 
amplified with primers that contain XhoI and XbaI restriction sites, TRL12-570-XhoI s (33) 
and TRL12-stop-XbaI as (34). The PCR products were cleaved with appropriate restriction 
enzymes and inserted into the expression vector pcDNA3-sig-HA containing the signal   27
sequence of TRL12 and in frame the epitope HA. The resulting plasmid, pcTRL12-sig-HA, 
encoded full-length fused to a N-terminal HA tag. The integrity of pcUL132myc/his was 
confirmed by DNA sequencing. 
 
Transient transfection of eukaryotic cells. COS7 cells were transfected with the respective 
DNAs using Lipofectamine 2000 reagent (Invitrogen, Karlsruhe, Germany) according to the 
manufacturer's suggestion except that the transfection mixture consisted of 1 μg of DNA, 95 
μl of Dulbecco's modified Eagle's medium, and 6 μl of Lipofectamine Plus reagent. The 
mixture was added to a cell culture dish (3.5-cm diameter, seeded with 2 × 10
5 cells 1 day 
before). After 48 h, cells were harvested, washed three times with phosphate-buffered saline 
(PBS), and stored at −20°C until used. 
 
Image analysis. COS7 cells grown on glass coverslips in 24-well plates were transfected with 
1 to 2 μg of plasmid DNA using Lipofectamine 2000. Fibroblasts, also grown on glass 
coverslips in 24-well plates, were infected with virus at a multiplicity of infection of 0.5.                   
24 hours to 48 hours later, the coverslips were washed and fixed in 2.0% paraformaldehyde in 
PBS. The fixed cells were permeabilized with Triton X-100 containing buffer (0,1%) and then 
blocked with PBS-1% bovine serum albumin. Primary antibodies, were then added. 
Following washing, antibody binding was detected with the appropriate secondary antibody 
conjugated with either fluorescein isothiocyanate or tetramethylrhodamine isothiocyanate 
(Dianova). Images were collected using a Zeiss Axioplan 2 fluorescence microscope fitted 
with a Visitron Systems charge-coupled device camera (Puchheim, Germany). Images were 
processed using MetaView software and Adobe Photoshop. 
Monoclonal antibodies utilized: mouse anti-MCP; mouse anti-IE-1 (p63-27); mouse anti-gB 
(27-287); mouse anti-gH (14-4B); mouse anti-pp150 (XP-1); Myc-specific monoclonal 
antibody; rabbit and mouse anti-HA; rabbit anti-calreticulin (endoplasmic reticulum marker; 
Dianova, Hamburg, Germany); rabbit anti-GM130 (Golgi marker; Dianova); sheep anti-
TGN46 (trans-Golgi network marker; Serotec) 
 
   28
Preparation of GST-TRL12 fusion protein and antiserum. The TRL12 carboxyl-terminal 
region was amplified from TR DNA by PCR with the following primers containing either 
BamHI or XhoI: TRL12-TR BamHI 5 (42) and TRL12-TR XhoI 3 (43). The PCR product was 
digested with both endonucleases and inserted into the expression vector pGEX-1P 
(Pharmacia Biotech, Freiburg, Germany). The resulting plasmid, GST/TRL12c, contained 
nucleotides (nt) 1123 to 1230 of TRL12-TR fused to the glutathione S-transferase (GST) 
gene. Correct insertion was confirmed by DNA sequencing. Plasmid DNA was used to 
transform Escherichia coli BL21 for expression of GST fusion proteins. The fusion protein 
was induced and purified from E. coli lysates according to the manufacturer’s instructions. 
The 34-kDa fusion, was used to raise an antiserum in mice.  
 
Immunoprecipitation. Immunoprecipitation of Myc-containing proteins was carried out with 
the  μMACS c-Myc-tagged protein isolation kit (Miltenyi Biotec, Bergisch-Gladbach, 
Germany) according to the manufacturer’s instructions.  
 
SDS-PAGE and immunoblotting. Lysates of infected cells were incubated in sample buffer 
containing 15 mM Tris-Cl (pH 6.8), SDS, 2% (vol/vol), b-mercaptoethanol, 10% (vol/vol) 
glycerol, and 0.01% bromophenol blue for 20 minites at room temperature. The samples were 
boiled at 95°C  for 5 min and the centrifugated at 10 000 g. Proteins were separated by 
sodium dodecyl sulfate-polyacrylamide
  gel electrophoresis (SDS-PAGE) on 10 to 15% 
polyacrylamide gels
  under standard conditions. Proteins were transferred to nitrocellulose
 
membranes, and membranes were blocked with PBS containing 0.1%
  Tween 20 and 5% 
powdered milk. Antibodies and sera were diluted
  in PBS containing 0.1% Tween 20. 
Antibody binding was detected with horseradish peroxidase-coupled anti-murine 
immunoglobulin and the ECL detection system (Pharmacia Biotech, Freiburg, Germany). 
 
BAC mutagenesis and reconstitution of TRL12 recombinat viruses.  Mutagenesis of 
TR12 was performed using linear DNA fragments for homologous recombination. 
Recombinant viruses on the genetic background of strain TR12 were constructed using TR-
BAC (GenBank AC146906).    29
 
Deletion mutant Del-TRL12 was created by site-directed mutagenesis using a PCR-generated 
fragment electroporated into Escherichia coli strain DH10B harbouring the TR bacterial 
artificial chromosome (BAC) and expressing bacteriophage λ functions redαβγ from plasmid 
pkD46 (Datsenko, K.A. et al. 2000 – GenBank AY048746). The primers that were used to 
generate the recombination fragments represented hybrids in which the 5′ end was 
homologous to sequences flanking the HCMV region to be deleted (50 nucleotides) and 3′ 
ends were homologous to the kanamycin resistance gene as present in plasmid pcpo15-Link2 
(30 nucleotides). PCR amplification of the recombination fragment was performed with 
primers  TRL12-TR Kan5(44) and TRL12-TR Kan3(45). Thus, the resulting PCR product 
consisted of a kanamycin resistance gene flanked by short stretches of HCMV-specific 
sequences. 
The PCR-fragment was electroprorated into E.Coli DH10B carrying the TR-BAC and the 
plasmid pkD46 for recE/T mediated recombination. Following homologous recombination in 
Escherichia coli, colonies carrying kanamycin and chloramphenicol resistance were selected 
on agar plates containing kanamycin (30μg/ml) and chloramphenicol (30μg/ml). 
To confirm the integrity of the recombined BAC, digestion of DNA with the appropriate 
restriction enzymes was carried out and analyzed via agarose gel electrophoresis in 
comparison to the parental TR-BAC. To confirm recombination at the predicted site PCR 
analysis as well as DNA sequence analysis of the TRL11-TRL13 region was performed. 
The resulting BAC-Del-TRL12 was used for transfection of fibroblasts and reconstitution of 
infectious virus Del-TRL12.  
 
Recombinant myc-tagged virus. To create BAC-TRL12myc a PCR fragment was generated 
using HCMV/kanamycin hybrid primers as described above. PCR amplification was 
performed with primers BAC-TRL12myc-s(80) and BAC-TRL12myc-as(81). The 5′ primer 
contained an additional sequence coding for the myc epitope (AEEQKLISEEDLL). This PCR 
fragment was used for recombination in BAC-TR12 as described above.  
 
Reconstitution BAC-derived virus RV-delTRL12/TR12  . MRC-5 cells (2,5 x 10
5  cells per 
well) were seeded into six-well dishes. Two days later, 1 μg of HCMV BAC DNA, prepared 
using Nucleobond PC 100 columns (Macherey-Nagel, Düren, Germany) together with 1 μg of 
pcDNApp71tag plasmid DNA  was cotransfected with the Superfect reagent (QIAGEN, 
Hilden, Germany). Serum-free Dulbecco's modified Eagle's medium was added to the   30
transfection mixture to a total volume of 100 μl and incubated for 30 min at room 
temperature. MRC-5 cells were serum starved for 30 min and subsequently 1 ml of 
Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum was added 
together with the transfection mixture for 4 h at 37°C. After removal of the transfection 
mixture the cells were incubated for 7 days in cell culture medium. The cells were split and 
cultured until a cytopathic effect was observed. Propagation of the infectious virus was 
through cocultivation of infected and uninfected cells. To test for reversion of the 
recombinant viruses, primers X and Y were used. 
 
Viral DNA Accumulation analysis by Real-Time PCR. For analysis of viral DNA 
accumulation during infection, intracellular particles from TR and Del-TRL12 were used to 
infect 6 x 10
4 fibroblast in 24 well-dishes at MOI 0,1. DNA copy numbers were analyzed on 
days 1, 3, 6, 9 and 12  after infection by quantitative real time PCR. 
 
Multistep growth curves for TR-based viruses. Intracellular particles were directly used to 
assay the growth kinetics of the viral mutants. To this end, 1 day after seeding 2,5 × 10
5 HFF 
per well in 6-well plates, cells were infected with wild type virus (TR) and TRL12 deletion 
mutant (Del-TRL12) at MOI of 0,5 in a volume of 1 ml. After incubation at 37°C for 4 h the 
infectious mixture was removed, cells were washed twice with PBS, and fresh medium was 
added. At days 3, 6, 9 and 12 after infection, the cells were harvested and intracellular 
particles were isolated as described above. Different dilutions of these virus preparations were 
used directly to determine the virus titre by indirect immunofluorescence using a monoclonal 
antibody (MAb) against the immediate early protein 1 (IE1) of HCMV as described.  
 
DNA sequence analysis. To establish the coding sequences for TRL12 in clinical isolates, 
DNA was extracted from lysates of infected fibroblasts and amplified by PCR using primers 
TRL11 EcoRI(59) and TRL13-TR BamHI(62). Nucleotide sequences were determined on an 
ABI 377 using the dye terminator sequencing kit according to the manufacturer’s instructions 
(PE Applied Biosystems, Foster City, Calif.).  
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Sequence and phylogenetic analysis. The nucleotide and amino acid sequence described in 
this study were aligned using the ClustalW software and displayed as a printable output by 
BOXSHADE Server (http//www.ch.embnet.org/software/BOX_form.html). Phylogenetic 
analysis was performed by Hein method and the lasergene’99 System package (DNASTAR), 
choosing the MegAlign option. Phylogenetic analysis was confirmed by ClustalW software 
and MEGA software alignment and tree display methods. 
Nucleotide accession numbers. TR-BAC (GenBank AC146906); 
 
PRIMERS 
 
TRL12-TR Kan5 (44) 
5’ACCGTCAAAGACGCAACAACCTTACGTACCGACAAACGGTATATGTAATTAGT
CACGACGTTGTAAAACGACGGCCAGTG – 3’ 
 
TRL12-TR Kan3 (45) 
5’TAGTGTGCGTGCCATGTGAGATGTCATAGTGACCTGTTTTGCGCATAAGAAGCT
TCAAAAGCGCTCTGAAGTTCCTATAC - 3’ 
 
BAC-TRL12myc-s (80) 
5’AGATGATATTAGTGAATCTAGCCTTGTTGTGCAATATCATCCTGAACATGAAGA
CGAACAAAAACTCATCTCAGAAGAGGATCTGTAAAGTCACGACGTTGTAAAACG
ACGGCCAGTG - 3’ 
 
BAC-TRL12myc-as (81) 
5’ATTCCGAAAACGTGGATATGATTACCGTCCATGTAATCGCAAGATGCCAGTGCA
TAGCTTCAAAAGCGCTCTGAAGTTCCTATAC - 3’ 
 
TRL12-TR 5 (39) 
5’- CACCAAGCTTATGCGCGTCAACCGTCAAAG -3’ 
 
TRL12-TR 3 (40) 
5’- GGTAGAATTCGTCTTCATGTTCAGGATG -3’ 
 
RecTRL12myc-as (85) 
5’- ATTCCGAAAACGTGGATATGATTACCG -3’ 
 
TRL12-TR BamHI (42) 
5’ – CTCAGGATCCATGCTTCTTTTTTTTGTTC -3’ 
 
TRL11 EcoRI (59) 
5’ – TTATGAATTCTGGTTACGGATTCCCAAGAGG -3’ 
 
TRL13-TR BamHI (62) 
5’ – CACTGGATCCGTATTTGTCGTAGCAGTTGG – 3’ 
   32
TRL12-TR rec3 (53) 
5’ – TAGTGTGCGTGCCATGTG – 3’ 
 
Kan 2,5 (63) 
5’ – CTCATGCTGGAGTTCTTC – 5’ 
 
TRL12-570-XhoI as (32) 
5’ – ATGGCTCGAGTGGAGTTGATTTCACAGG – 3’ 
 
TRL12-33-EcoRI s (82) 
5’ – ATGGGAATTCAGCACCGATACCAACAAT – 3’ 
 
TRL12-570-XhoI s (33) 
5’ – ATGACTCGAGCTAACGGCAGAAGAAGG – 3’ 
 
TRL12-stop-XbaI as (34) 
5’ – ATTGTCTAGATTAGTCTTCATGTTCAGG – 3’ 
 
TRL12-TR XhoI 3’ (43) 
5’ – ACTTCTCGAGGTCTTCATGTTCAGGATG – 3’ 
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 ORF TRL12: GENERAL FEATURES 
 
Human cytomegalovirus has a glycoprotein coding capacity which far exceeds that of other 
herpesviruses. The genome of the laboratory-adapted strain AD169 encodes at least 57 open 
reading frames (ORFs) with predicted characteristics of glycoproteins or glycoproteins exons. 
Remarkably, fewer than 10 glycoprotein gene products have been characterized with respect 
to biosynthesis, function, and incorporation into the virion. The envelope glycoproteins of 
herpesviruse have multiple role in the viral replication cycle, including essential functions 
such as attachmen, penetration, cell-to-cell spread, envelopment and maturation of nascent 
virus particles. To understand these processes, it necessary to have detailed knowledge of the 
structure and function of envelope glycoproteins.  
The reading frame TRL12 of cytomegalovirus codes for a protein of approximately 417 
amino acids which has all characteristics of a type I glycoprotein. 
The only information available about TRL12 gene concerns its transcription kinetic. 
Preliminary results (unpublished data) indicate that TRL12  protein is encoded by a 2,4 or 2,7 
kb mRNA with a early-late kinetic. 
 
Chee et al. [62] identified nine multigene families in AD169 strain and an additional three 
were recognized in low passage isolates [141]. One, the RL11 family consists of 12 genes 
(RL11, RL12, RL13, UL1, UL4, UL5, UL6, UL7, UL8, UL9, UL10 and UL11) oriented left 
to right near the left terminus of the genome and arranged contiguously but for the presence 
on the opposing strand of two unrelated genes (UL2 and UL3). RL11, RL12 and the 5’-
portion of RL13 are present twice in the AD169 genome by virtue of their location in an 
inverted repeat. This repeat is much smaller in low passage strains, which consequently 
contain  single copies of these genes [44]. All members of the RL11 family (generically 
termed “RL11 genes”) are also present in CCMV, which has counterparts of all but UL1 
[142]. Cytomegalovirus of mouse, rat and tupaia lack RL11 genes [143, 39, 144]. These 
proteins that are expressed only by individual genera of a herpesvirus subfamily are termed 
“private proteins” and could contribute to the specific properties of individual herpesviruses, 
such as cell tropism or pathogenicity.  
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RESULTS 
 
 
1. GENOMIC LOCATION OF TRL12 IN HCMV GENOME AND PREDICTED 
FEATURES OF THE PROTEIN.  
 
HCMV AD169 and low-passage isolates differ in two major aspects. First, as originally 
reported for Toledo, low-passage
 isolates contain a DNA segment that is absent from AD169 
(UL133
  to UL151). Second, low-passage isolates lack an internal
  long repeat (IRL). A 
deletion and duplication produced these
 changes in AD169.  
The coding region  for gpTRL12 is located within the repeat sequences flanking the long 
unique segment of the viral genome (terminal repeat long (TRL) and internal repeat long 
(IRL)). In the laboratory adapted HCMV strain AD169 the reading frame is present twice and 
termed TRL12 and IRL12, respectively. In contrast, all low passage clinical isolates examined 
so far contain only the TRL12 reading frame since large parts of IRL including IRL12 are 
replaced by unique coding sequences. Thus, besides the fact that extensively passages HCMV 
strains have lost a substantial part of the coding sequence, low passage isolates have the 
advantage that only a single copy of the TRL12 gene needs to be deleted. The integrity
 of 
TRL12 was conserved in all HCMV strains during these deletion/recombination/inversion
 
events, suggesting an important function of TRL12 for replication. 
The ORF TRL12 of AD169 codes for a protein of 416 amino acids
  with a theoretical 
molecular mass of 47,4 kDa. Computer predictions
  classify the TRL12 polypeptide as a 
typical type I glycoprotein
  with a signal sequence between amino acids 1 and 30 and a 
membrane
 anchor between residues 370 and 390 (Fig. 5). The predicted primary amino acid 
sequence of TRL12 AD169 contains 17 motifs for addition of N-linked
  carbohydrate 
modification and several motifs
  for O-linked glycosylation in the extraluminal
  domain of 
TRL12. 
The short cytoplasmatic tail contains the motifs, YXXΦ that is known to be implicated in 
endosomal/lysosomal targeting. 
The extracellular domain contains a region encompassing ~ 120 amino acids, containing 
several cysteins residues, which may be involved in disulfide bonding. This region has been 
found to be similar to the CR domain of adenovirus E3 proteins which has an 
immunoglobulin-like (Ig-like) fold (INTERPRO IPR013783) (Fig. 6B). Domains with an Ig-
like fold consists of a beta-sandwich of seven or more strands arranged into two sheets   35
usually linked by conserved Cys residues (Fig. 6C). One feature of Ig-like domains is that 
they contain relatively few highly conserved residues. These domains are often involved in 
interactions.  
 
 
2. ANALYSIS OF TRL12 POLYMORPHISM 
 
Reading frame TRL12 from 30 cytomegalovirus strains has been amplified and sequenced. 
Comparison of sequences showed that this locus is highly variable between different HCMV 
isolates. Phylogenetic analysis, performed on nucleotide and amino acid sequences, revealed 
that the identified variants are not randomly distributed, but are clearly clustered in 4 distinct 
groups (Fig. 6A) The four main groups diverged on the amino acid level in the rage of 60-
70% and showed a high level of amino acid identity  (80-100%) among strains within each 
group. 
Alignment of TRL12 amino acid sequences of clinical strains and comparison using the 
AD169 sequence as the arbitrary reference sequence, showed that amino acid variation is 
dispersed over all the protein sequence (Fig. 7). In particular, high variability is evident in the 
N-terminal region, predicted to be the extracellular domain of the protein in which are 
concentrated most of post-translational modification sites (N- and O-glycosylation sytes). 
Despite the impressive variability of the amino acid sequence, the Ig-like domain is conserved 
in its structure as well as the number and the position of cysteine residues confirming that 
there is a very tight constrain upon this domain (Fig. 6B). 
 
3. CLONING, RECOMBINAT EXPRESSION OF pTRL12 AND INTRACELLULAR 
DISTRIBUTIN OF THE PROTEIN 
 
To analyze the protein product of ORF TRL12 in the absence
 of viral infection, the coding 
sequence from strain TR was
 inserted into the vector pcDNA3myc/his, allowing the synthesis
 
of a pTRL12 protein containing an epitope-tagged carboxyl terminus.
  Furthermore, the 
TRL12 coding sequence was inserted into the vector pcDNA-sig-HA, containing the TRL12 
signal sequence cloned in frame with the HA epitope. The resulting plasmid, pcTRL12-sig-
HA, encoded full-length TRL12 fused to a N-terminal HA tag (Fig. 8A).  
Following transient transfection in COS7 cells, the protein
 was analyzed 24h and 48h after 
transfection by indirect immunofluorescence (IIF) using a Myc-specific monoclonal
 antibody 
and/or a HA-specific monoclonal antibody.    36
The protein pTRL12 shows an exclusively cytoplasmatic localization. The intracellular 
staining patter of pTRL12 detected with anti-HA and -Myc antibodies were indistinguishable. 
With both antibodies a perinuclear vesicles and tubular compartment and numerous vesicles 
in the periphery of the cell were stained. The staining was mainly associated with very 
irregular granules or vesicle-like structures that were especially condensed near the nucleus 
(Fig. 8B). In cells expressing very high amounts of pTRL12-HA, cell surface expression of 
pTRL12 was detected in immunofluorescence by using monoclonal antibody anti-HA  
(Fig. 8C). 
To better define the intracellular distribution of pTRL12, has been used transient expression 
of pHA-TRL12 followed by fluorescence imaging with antibodies directed against the HA-
tagged viral protein and against cellular markers of the secretory pathway (Fig. 9) 
Hardly any colocalization with endoplasmic reticulum (ER) marker calreticulin was found. 
Recombinant pTRL12 had a vesicular staining patter that largely colocalize with TGN46, a 
marker of the trans-Golgi network, that shows an altered morphology comparable to that 
observed for several HCMV glycoproteins during the infection. Minimal overlap of the signal 
with markers for the Golgi (GM130) was found. The ability of recombinantly expressed 
pTRL12 to mediate its own localization to the TGN demonstrates that HCMV pTRL12 
contains all of the cis-acting elements necessary for TGN localization. Inspection of the 
pTRL12 cytoplasmic domain for the presence of trafficking motifs that are known to function 
in others viral proteins reveals a number of motifs that may be involved in the intracellular 
trafficking of HCMV pTRL12. 
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4. TRL12 PROTEIN EXPRESSION  IN INFECTED CELLS  
 
Immunoblot analyses were carried out to characterize the expression
 of pTRL12 in infected 
cells. Fibroblasts
 were infected with wild-type strain TR and mutant virus del-TRL12 and cell 
lysates were prepared
 96 h post infection. In infected cells, one major signal at 97-150 kDa 
was
 observed using a mouse anti-TRL12 serum raised against the carboxyl terminus of the 
protein (see Materials and Methods). Control analysis using a monoclonal
 antibody specific 
for gB (p27-287)  showed the expected molecular-weight. (Fig. 10A) 
The theoretical molecular mass of TR-TRL12 is 47,4 kDa. Thus, the
 97- to 150-kDa protein 
most probably represents fully modified
  gpTRL12, carrying N-linked and O-linked 
carbohydrates. The diffuse migration as well
 as the presence of multiple bands, however, 
indicated that the
 protein carried some modification.  
To obtain more information about the nature of the 97- to 150-kDa
 protein it was performed 
an immunoprecipitation  analysis using lysates of cells infected with a recombinant virus TR-
TRL12-Myc expressing
 gpTRL12 containing a Myc epitope tag at the carboxyl terminus
 (the 
construction of recombinant viruses is described collectively
 below). As shown in (Fig. 10B), 
the protein recognized by an anti-Myc
  monoclonal antibody were identical to the signals 
obtained with
 the polyclonal anti-TRL12 mouse serum. 
A hallmark of many HCMV glycoproteins that have been identified
 thus far is the formation 
of disulfide-linked homomeric or heteromeric
  protein complexes. Therefore, complex 
formation of
 gpTRL12 was analyzed in cells infected with the recombinant virus TRL12myc. 
Immunoprecipitation analysis of viral
 lysates carried out  in the absence of reducing agents 
showed a migration
 pattern of gpTRL12 (Fig. 10B) that was unchanged compared
 to that 
under reducing conditions observed in western blot (Fig. 10A), indicating that gpTRL12 is
 not 
part of a disulfide-linked complex.  
 
 
4.1 Intracellular localization of gpTRL12 in infected cells. 
To define the intracellular localization of gpTRL12 in infected
 cells, fibroblasts infected with 
recombinant virus
 TR-TRL12-Myc. Since the anti-pTRL12 antiserum was less sensitive and 
gave a higher background than the monoclonal anti-Myc antibody; therefore it was not 
possible to detect the untagged protein. The cells were infected for 72 h and used
  for 
fluorescence imaging with antibodies directed against the Myc epitope.
  In infected cells   38
gpTRL12myc accumulated in a juxtanuclear location, corresponding to the trans-Golgi 
network, which has been argued to constitute the virus assembly compartment [8]. (Fig. 10C) 
 
5. CONSTRUCTION OF TRL12 RECOMBINANT VIRUSES. 
Aim of these experiments was to characterize the importance of pTRL12 in the viral 
replication cycle. To this we generated a deletion mutant in a low passage HCMV isolate 
(TR) for two main reasons: (i) AD169, the laboratory adapted HCMV strain does not contain 
the full set of genes characteristic for HCMV; (ii) the ULb’ region, which is missing in 
AD169, encodes a number of glycoproteins which potentially could interact with pTRL12. 
 
In order to investigate the role of pTRL12 in the replication of HCMV, a series of 
recombinant viruses were generated, using a strategy that includes the use of an infectious 
clone of HCMV maintained as a bacterial artificial chromosome in E. Coli. All manipulations 
were carried out in bacteria and mutations are introduced into the HCMV BAC using linear 
PCR fragments. This methodology takes advantage of the lambda phage recombination 
system (RED locus) expressed from an inducible promoter that enables the use of a linear 
single-stranded DNA to target genes of interest carried on BACs maintained in E Coli.  
 
5.1 Generation of BAC-delTRL12-TR 
 
To elucidate the role of pTRL12 in HCMV replication, a deletion mutant lacking the entire 
TRL12 open reading frame was generated. 
To generate a TRL12 null mutant, BAC technology has been employed [145]. The basic 
strategy is to replace the TRL12 locus in the HCMV genome (TR-BAC) with a selectable 
antibiotic resistance gene that is generated by PCR using primers with homology extensions. 
The PCR fragment was electropored into bacteria harboring the HCMV TR genome as BAC 
as well as the pKD46 plasmid encoding the recombination functions of phage λ (for a detailed 
description, see Materials and Methods). The predicted recombination product would have the 
ORF TRL12 deleted and replaced by the kanamycin resistance gene. 
The TR-BAC was preparated from the TR clinical isolate. The BAC clone was generated by 
substituting BAC cassette for the US2-US5 region of the TR genome by using the method of 
Borst et al.[120].  TR-BAC carries the chloramphenicol resistance cassette.    39
The PCR fragment was generated by using primers with 50-nt extensions that are homologous 
to regions adjacent to the gene to be deleted and 30-nt priming for the template plasmid, pCP-
o15, carrying the kanamycin resistance gene that are flanked by FRT (FLP recognition target) 
sites (Fig. 11) 
PCR products were gel-purified, treated with DpnI and then transformed into bacteria 
carrying the TR-BAC and the Red helper plasmid (pKD46). Insertion of the cassette resulted 
in the deletion of the entire TRL12 ORF except for 60 bp of the 5’end and 190 bp of the 3’. 
Colonies carrying BACs with the ORF TRL12 deleted were isolated after overnight 
incubation at 37°C on Cm/Km selective plates. Two BAC cloneS, designed BAC-delTRL12-
TR were further characterized. 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 11. Schematic overview of BAC mutagenesis using the helper plasmid (left). Generation of PCR 
recombination fragment using megaprimers with 50-nt extention that are homologous to regions adjacent to the 
gene to be deleted and 30-nt priming for the template plasmid, pCP-o15. 
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5.2 Characterization of  BAC-delTRL12-TR 
 
The DNA of the resulting BAC was analyzed for overall integrity by restriction analysis, PCR 
analysis and nucleotide sequencing in the interested genomic region.  
BAC-DNA from both the wild-type TR and the recombinant BAC-delTRL12-TR was 
isolated, digested with BglII and EcoRI and analyzed on a 0,6% agarose gel and restriction 
patterns were compared in order to verify that no spurious rearrangements had occurred 
during the recombination process (Fig. 12A). 
In BAC-delTRL12-TR, replacement of TRL12 with the kanamycin cassette caused an 
additional BglII restriction fragment since the kanamycin gene from pCP-o-15 contains a 
single BglII site (Fig. 12C). 
 
PCR analysis over the BAC-DNA from both the wild-type and the recombinant BAC-
delTRL12-TR showed the correct replacement of the ORF TRL12 by the kanamycin gene. 
PCR analysis was performed using the pair primers: TRL11EcoRIs(59)/TRL13BamHI as (62), 
TRL11EcoRIs(59)/TRL12TRrec3(53),  TRL11EcoRIs(59)/Kan2,5(63). With the first set of 
primers, a 2,2 Kbp fragment was amplified from the recombinant BAC-delTRL12-TR as 
predicted due to the presence of the kanamycin cassette and a 1,7 Kbp  PCR product was 
obtained from the parental BAC-TR. With the second set of primers, a 1,9 Kbp fragment was 
predicted for the recombinant BAC-delTRL12-TR and a 1,3 Kbp fragment for the wild type 
BAC-TR. With the third set of primers, a 0,5 Kbp fragment was predicted for the recombinant 
BAC-delTRL12-TR; no amplification product for the wild-type BAC-TR was predicted since 
the primer Kan2,5 anneals specifically to the kanamycin cassette sequence (Fig. 12B). 
 
Taken together, the results of restriction, PCR and sequencing analyses showed that 
recombination events took place at the correct sites of the HCMV genome. 
 
5.3 Generation of recombinant myc-tagged virus: BAC-TRL12myc-TR 
 
To create BAC-TRL12myc a PCR fragment was generated using HCMV/Kanamycin hybrid 
primers as described above. The 5′ primer contained an additional sequence coding for the 
Myc epitope (AEEQKLISEEDLL). This PCR fragment was used for recombination in BAC-
TR12 as described above. PCR products were gel-purified, treated with DpnI and then 
transformed into bacteria carrying the TR-BAC and the Red helper plasmid (pKD46).   41
Insertion of the cassette resulted full-length TRL12 fused to a C-terminal Myc tag. Colonies 
carrying BACs with the ORF TRL12 fused with Myc tag were isolated after overnight 
incubation at 37°C on Cm/Km selective plates. Two BAC clones, designed BAC-TRL12myc-
TR were further characterized. 
 
 
5.4 Characterization of  BAC-TRL12myc-TR 
 
The DNA of the resulting BACs were analyzed for overall integrity by restriction analysis, 
PCR analysis and nucleotide sequencing in the interested genomic region.  
BAC-DNA from both the wild-type TR and the recombinant BAC-TRL12myc-TR was 
isolated, digested with BglII and EcoRI and analyzed on a 0,6% agarose gel and restriction 
patterns were compared as described above (Fig. 13A). 
In BAC-TRL12myc-TR, insertion of the kanamycin cassette caused an additional BglII 
restriction fragment since the kanamycin gene from pCP-o-15 contains a single BglII site. 
Insertion of the Myc epitope sequence at the C-terminal of TRL12 caused an additional EcoRI 
restriction fragment (Fig. 13B). 
 
PCR analysis over the BAC-DNA from both the wild-type and the recombinant BAC-
TRL12myc-TR showed the correct insertion of the Kanamycin cassette. PCR analysis was 
performed using the primers: RecTRL12myc-as (42) and TRL12-TR-BamHI (85). A 1,8 Kbp 
fragment was amplified from the recombinant BAC-TRL12my-TR as predicted due to the 
presence of the kanamycin cassette. As predicted, a 350 bp  PCR product was obtained from 
the parental BAC-TR. Sequencing analysis showed the in frame insertion of the Myc epitope 
at the C-terminal of TRL12 (Fig. 13C). 
Taken together, the results of restriction analysis, PCR and sequencing showed that 
recombination events took place at the correct sites of the HCMV genome. 
 
5.5 Reconstitution of infectious TRL12 recombinant viruses 
 
To test whether the recombinant BACs could be reconstituted to infectious viruses, BAC 
DNA was purified from BAC-containing E.Coli and transfected into MRC-5 cells to 
reconstitute recombinant virus. Cotransfection of a pp71 expression plasmid led to a 30-fold 
enhancement in plaque formation as described [10]. One week after transfection, the cells   42
were transferred to 2-cm
2 flasks and cultured for about 2 weeks until plaques appeared. 
Particles could be reconstituted from the recombinant BACs, indicating that the TRL12 ORF 
is not absolutely necessary for viral growth. 
 
6. GROWTH PROPERTIES OF TRL12 MUTANT VIRUS 
 
6.1 Analysis o f plaque formation and virus spread 
 
Concomitant with productive infection, HCMV induces cytopathogenic effects (CPE) in 
tissue cultures of various origins, which include cell rounding, cell enlargement, formation of 
inclusion bodied and lysis of infected cells. 
Most HCMV strains require adaptation to HF cells in culture before they replicate efficiently 
in these cells. Recent clinical isolates are distinguished from cell culture adapted strains by 
lack of release of cell-free infectious progeny from infected cells. The progeny virus is highly 
cell-associated and development of CPE or plaques can take as long as several weeks, 
requiring subculture of infected cells. In contrast, both AD169 and Towne form distinctive 
plaques in less than 7 days and a single round of replication resulting in cell free virus in the 
culture fluid requires 96h or less to complete.   
In order to study the morphology and the size of plaque formation, human fibroblasts (HF) 
were infected with Del-TRL12 and TR viruses at multiplicity of 0,5 PFU/cell.. After 4 h the 
viral inoculum was removed, the cells were washed and subsequently incubated 10 days at 
37°C until approximately 80% of the cells showed CPE. 
In Fig. 14A a comparison of representative plaques in culture infected with Del-TRL12 and 
TR is shown. The morphology of the plaque induced by TR is characterized by the formation 
of small foci, a typical plaque morphology associated to a cell-associated spread; whereas, 
infection with Del-TRL12 leads to an even distribution of the infection through the cell 
culture. 
In order to further investigate the plaque formation properties, fibroblasts were infected with 
Del-TRL12 and TR (multiplicity of infection of 0,5 PFU/ml) and assayed 3, 10 and 14 days 
post infection for expression of HCMV IE-1 by immunofluorescence. (Fig. 14B). At day 10 
post infection, the TRL12 deletion mutant Del-TRL12 induced plaques significantly larger 
than those induced by the wild-type virus TR. At day 14 post infection the Del-TRL12 plaque 
extension might be consistent with the spread of infection via supernatant. 
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6.2 Growth kinetic of Del-TRL12 virus 
 
 
To investigate possible effects of TRL12 deletion on the kinetic of virus replication and to 
extend the findings of the plaque size determinations, multi-step growth kinetic of the 
engineered mutant virus, Del-TRl12, were performed. The extremely low to non-existent 
infectivity present in the  
 
 
Figure 15: Replication of TRL12 mutant virus. Fibroblasts were seeded in six-well dishes and infected with 
TR and Del-TRL12 viruses (multiplicity of infection, 0.5). At the indicated days post infection, cells were 
harvested and intracellular particles were isolated and titrated using indirect immunofluorescence with an 
antibody directed against the immediate-early antigen 1. Each data point represents the mean of three 
independent infected cultures. 
TR: wild type strain; Del-TRL12: recombinant virus lacking ORF TRL12. 
 
 
tissue culture supernatant of TR strain made it impossible to analyze the replication kinetics 
using extracellular virus. Therefore, intracellular particles were isolated for this assay (see 
Material and Methods). Preparations from both TR and Del-TRL12 contained sufficient 
infectious virus to perform multistep growth curves. Fibroblasts were infected with identical 
amounts of infectious virus (MOI.= 0,5) from either the parental virus TR or the mutant Del-
TRL12. The virus titers from cells infected with TR and Del-TRL12 were determined over a 
period of 12 days. Experiments were done in triplicate and the results are summarized in  
Fig. 15. 
 
Strikingly, the final virus yield from cells infected with Del-TRL12, obtained after 12 days of 
infection, was increased approximately 10-100 fold as compared to wild type parental virus 
TR. At day 9 post infection, the deletion mutant Del-TRL12 reached a titer of 4,5 x 10
3   44
PFU/ml and declined thereafter, whereas the parental strain TR reached titers of 
approximately 50 PFU/ml that slightly increased at the day 12 post infection. 
 
The number of HCMV immediate early protein-positive nuclei was comparable 24h after 
infection indicating that the infection rate of fibroblasts was not affected by TRL12 gene. 
These results indicated that the deletion of ORF TRL12 from the genome of low-passage 
HCMV strain accelerated and increased virus production in fibroblasts. Then, the locus 
TRL12 is detrimental to cytomegalovirus growth in fibroblasts. 
 
 
6.3 DNA accumulation after infection with Del-TRL12 
 
Viral DNA accumulation during infection has been analyzed by real-time PCR.  
Intracellular particles from TR and Del-TRL12 corresponding to 6 x 10
3 PFU/ml were used to 
infect fibroblasts. Viral DNA copy numbers were analyzed on days 1, 3, 6, 9, 12 after 
infection by quantitative real-time PCR, both in the supernatant and in the cellular pellet.  
 
As can be observed in Fig. 16 the ratio of viral DNA copies to infectious intracellular 
particles did not differ considerably between the two preparations (6 x 10
6 for TR and 10
7 for 
Del-TRL12). The relative ratio of viral DNA to infectivity suggests that the viral inoculum of 
Del-TRL12 contained the same number of infectious particles as the wild-type virus TR.  
Consistent with the results observed for the replication kinetic of Del-TRL12, the increase of 
Del-TRL12 infectious titers observed in Fig. 15 is reflected by an increase in intracellular 
viral DNA accumulation. As shown in Fig. 16A, at days 9 at 12 post infection, the number of 
viral genome copies from cells infected with Del-TRL12, was increased approximately 100 
fold as compared to wild type parental virus TR.  
Strikingly, as can been observed in Fig. 16B, disruption of TRL12 resulted in release of viral 
progeny to the medium, in contrast to the wild-type virus TR that, being a recent clinical 
isolates, is characterized by more cell-associated spread and by lack of release of cell-free 
infectious progeny from infected cells. It is further interesting to note that, at day 12 p.i., the 
slight drop in cell-associated viral yield (Fig. 15) and viral DNA copies (Fig. 16A) for Del-
TRL12 virus is associated to an increased release of viral genome (Fig. 16B) and virus 
progeny (data not shown) to the medium. 
Deletion of TRL12 resulted in a 10-100 fold increase in intracellular particles and a 
concomitant enhanced release of virus to the medium in HF culture. The results of growth   45
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kinetics and DNA accumulation are largely a reflection of virus-induced plaque size because 
the number of infected cells are dependent on the size of the plaque.  
     
     
 
A)                                                                     B)    
Figure 16. Analysis of viral DNA accumulation in cellular pellet (A) and in the supernatant (B) during 
infection with TR and Del-TRL12 viruses. Intracellular particles from TR and Del-TRL12 corresponding to 6 x 
10
3 PFU were used to infect fibroblasts. Viral DNA copy numbers were analyzed on days 1, 3, 6, 9, 12 after 
infection by quantitative real-time PCR, both in the supernatant and in the cellular pellet.   
  
 
 
6.4 Analysis of MCP, pp150, gB and gH expression in cells infected with Del-TRL12  
 
Fibroblasts cells were infected with wild-type virus TR and deletion mutant Del-TRL12 at 
multiplicity of infection 0,5 PFU/cell and were processed at 72 h post infection with 
antibodies specific for capsid protein (MCP), tegument protein (pp150) and envelope proteins 
(gB and gH). All these proteins appeared to localize in the same region  in wild type and 
deletion mutant infected cells. Therefore, the expression and localization of capsid, tegument 
and envelope proteins is not dependent on gpTRL12 accumulation. (Fig. 17) 
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DISCUSSION 
 
The coding capacity of human cytomegalovirus (HCMV) for glycoproteins by far exceeds 
that of other herpesviruses. Few of these proteins have been characterized so far. The gene 
product of reading frame TRL12 has been investigated.  
The coding region for gpTRL12 is located within the repeat sequences flanking the long 
unique segment of the viral genome (terminal repeat long (TRL) and internal repeat long 
(IRL)). In the laboratory adapted HCMV strain AD169 the reading frame is present twice and 
termed TRL12 and IRL12, respectively. In contrast, all low passage clinical isolates examined 
so far contain only the TRL12 reading frame since large parts of IRL including IRL12 are 
replaced by unique coding sequences. Thus, besides the fact that extensively passages HCMV 
strains have lost a substantial part of the coding sequence, low passage isolates have the 
advantage that only a single copy of the TRL12 gene needs to be deleted. The integrity
 of 
TRL12 was conserved in all HCMV strains during these deletion/recombination/inversion
 
events, suggesting an important function of TRL12 for replication. TRL12 does not have 
homologs in others herpesviruses. These proteins that are expressed only by individual genera 
of a herpesvirus subfamily are termed “private proteins”. These proteins likely play very 
critical roles in the in vivo replication and pathogenic behaviour of the respective viruses.  
 
The putative protein product of TRL12 is a glycoprotein with a theoretical mass of 47,4 kDa. 
Transcription analysis (unpublished data)  revealed that the gene is transcribed  with a early-
late kinetic from the laboratory-adapted strain AD169 and low-passage isolates. 
Immunoblot analyses were carried out to characterize the expression
 of pTRL12 in infected 
cells. One major signal at 97-150 kDa was
 observed using a mouse anti-TRL12 serum raised 
against the carboxyl terminus of the protein. 
Since, the theoretical molecular mass of TR-TRL12 is 47,4 kDa, the
 97- to 150-kDa protein 
most probably represents fully modified
  gpTRL12, carrying N-linked and O-linked 
carbohydrates. The diffuse migration as well
 as the presence of multiple bands, however, 
indicated that the
  protein carried some modification. According to computer-based 
predictions, gpTRL12 (AD169 strain) carries 19 sites for addition of N-linked glycosylation 
(NetNGlyc 3.1 server; http://www.cbs.dtu.dk) and several motifs
 for O-linked glycosylation 
(NetOGlyc 3.1 server; http://www.cbs.dtu.dk). Additional modifications such as 
phophorylation, which has also been detected on other HCMV structural glycoproteins such 
as gB, could further add to the diffuse migration patter see in PAGE.   47
In infected cells, gpTRL12myc accumulated in a juxtanuclear location, similar to others 
HCMV glycoproteins such as gB and gpUL132. This compartment has been shown to contain 
proteins found in the trans-Golgi network and late endosomesand  has been argued to 
constitute the virus assembly compartment. The structural glycoproteins must be targeted to 
this compartment and, late in infection, become concentrated within organelle. This proposed 
assembly pathway appears to be a default assembly pathway for all herpesviruses. 
Interestingly, the integrity of the Golgi/TGN was disturbed by the cytomegalovirus infection. 
In uninfected cells the Golgi/TGN was represented by a number of tubules, whereas in 
infected cells the Golgi/TGN exhibited a rather vesicular appearance. During HCMV 
infection was observed an expansion of the TGN from the normal ribbon-like staining patter 
of the TGN46 in uninfected cells to a more expanded mesh-like morphology after infection 
[34].  
The finding that recombinant gpTRL12 can be localized to the trans-Golgi network in the 
absence of other viral function demonstrates that, similar to other structural glycoproteins of 
HCMV such as gB and gpUL132, gpTRL12 contains all of the cis-acting elements necessary 
for trans-Golgi network localization. This is in contrast to a number of others HCMV 
structural glycoproteins, including gH, gM, gN and gpTRL10, which require complex 
formation with other viral proteins in order to reach the more distal parts of the secretory 
system [23, 55]. Inspection of the gpTRL12 cytoplasmic domain for the presence of 
trafficking motifs that are known to function in these processes reveals a number of motifs 
that may be involved in this intracellular trafficking. A tyrosine-based motifs YXXΦ (where 
Y is tyrosine, X is any amino acid and Φ is any bulky hydrophobic amino acid) was found. 
YXXΦ motifs mediate the incorporation of membrane proteins into transport vesicles due to 
interaction with cellular adaptor proteins. In addition, gpTRL12 contains acidic cluster motifs 
which potentially interact with the connector protein PACS-1 (phosphofurin acidic cluster 
sorting protein 1), which redirects proteins from the endosomes to the trans-Golgi network, a 
proposed site of tegument assembly and virion envelopment. Thus, it seems likely that 
trafficking of gpTRL12 involves transport to the plasma membrane and recycling from there 
to the endosomal compartment involved in virus envelopment. Future experiments will test 
this hypothesis. 
 
In order to investigate the role of pTRL12 in the replication of HCMV, a series of 
recombinant viruses were generated, using a strategy that includes the use of an infectious 
clone of HCMV maintained as a bacterial artificial chromosome in E. Coli.   48
A deletion mutant lacking the entire TRL12 open reading frame was generated in a low 
passage HCMV isolate (TR) was generated. 
Concomitant with productive infection, HCMV induces cytopathogenic effects (CPE) in 
tissue cultures of various origins, which include cell rounding, cell enlargement, formation of 
inclusion bodied and lysis of infected cells. 
Recent clinical isolates are distinguished from cell culture adapted strains by lack of release of 
cell-free infectious progeny from infected cells. The progeny virus is highly cell-associated 
and development of CPE or plaques can take as long as several weeks, requiring subculture of 
infected cells. In contrast, both AD169 and Towne form distinctive plaques in less than 7 days 
and a single round of replication resulting in cell free virus in the culture fluid requires 96h or 
less to complete.   
The morphology of the plaques induced by wild-type strain TR is characterized by the 
formation of small foci, a typical plaque morphology associated to a cell-associated spread; 
whereas, infection with deletion mutant Del-TRL12 leads to an even distribution of the 
infection through the cell culture. 
At days 10 and 14 post infection, the TRL12 deletion mutant Del-TRL12 induced plaques 
significantly larger than those induced by the wild-type virus TR. The plaque extension might 
be consistent with the spread of infection via supernatant. 
To investigate possible effects of TRL12 deletion on the kinetic of virus replication and to 
extend the findings of the plaque size determinations, multi-step growth kinetic of the 
engineered mutant virus, Del-TRl12, were performed. 
Strikingly, the final virus yield from cells infected with Del-TRL12, obtained after 12 days of 
infection, was increased approximately 10-100 fold as compared to wild type parental virus 
TR. These results indicated that the deletion of ORF TRL12 from the genome of low-passage 
HCMV strain accelerated and increased virus production in fibroblasts. Then, the locus 
TRL12 is detrimental to cytomegalovirus growth in fibroblasts.  
 
Consistent with the results observed for the replication kinetic of Del-TRL12, the increase of 
Del-TRL12 infectious titers is reflected by an increase in intracellular viral DNA 
accumulation. At days 9 at 12 post infection, the number of viral genome copies from cells 
infected with Del-TRL12, was increased approximately 100 fold as compared to wild type 
parental virus TR.    49
Strikingly, disruption of TRL12 resulted in release of viral progeny to the medium, in contrast 
to the wild-type virus TR that, being a recent clinical isolates, is characterized by more cell-
associated spread and by lack of release of cell-free infectious progeny from infected cells. 
Deletion of TRL12 resulted in a 10-100 fold increase in intracellular particles and a 
concomitant enhanced release of virus to the medium in HF culture. The data are most 
compatible with an increased cell-to-cell spread of the delta-TRL12 recombinant virus. The 
results of growth kinetics and DNA accumulation are largely a reflection of virus-induced 
plaque size because the number of infected cells are dependent on the size of the plaque. This 
increase results in larger plaques which, in turn, lead to increased virus yield in the growth 
curve experiment since virus from the entire culture was assayed.. The increased number of 
infected cells will probably also produce a higher number of infectious particles in the 
supernatant. The increased number of infected cells will probably also produce a higher 
number of infectious particles in the supernatant. It is believable to explain the higher titres of 
cell-associated virus of Del-TRL12 compared to the wild-type virus TR,  by a faster spread 
via the supernatant. The PCR also indicates that the rate of viral DNA synthesis is not 
different between wt and delTRL12 in the early phases after infection. The higher yield at 
later times might reflect the increased number of infected cells due to increased spread.  
Expression of pTRL12 (wild-type virus, TR) delayed and reduced virus production in 
fibroblasts and supported cell-associated virus spread leading to the formation of small foci 
rather than to an even distribution of the infection through the cell culture. 
These data, clearly indicates that there is a negative effect of the TRL12 gene product on 
growth properties of limited  passaged cytomegalovirus strains in fibroblast cell culture.  
It could be speculated that the reduced virus production was due to a change in the virus-
release phenotype. The TRL12 protein apparently seems to be involved in redirecting the 
virions to more cell-associated, and therefore slower, spread. This is the reverse of what is 
selected for when clinical isolates are adapted for productively in fibroblasts cultures. 
Further experiments, where cell-cell-spread is inhibited by agarose overlay or by addition of 
neutralizing antibodies will clarify the point. It will be interesting to find out whether the 
increased plaque size has something to do with the virion envelope or an altered plasma 
membrane or both.  
 
A number of glycoproteins have been described as polymorphic [50, 51, 52]. A consequence 
of variations in structural glycoproteins could be a strain specific humoral immune response 
that incompletely protects against infection from a genetically divergent HCMV strain. 
However, although it is known that the humoral immune response against HCMV carries a   50
strain specific component, little is known about the antigens involved. Since, due to the 
exquisite species-specificity of HCMV, no animal model exists for the analysis of potential 
vaccines, as much knowledge as possible must be gained from detailed analysis of HCMV 
glycoproteins with respect to strain variations, function during the viral replication cycle and 
induction of  a protective humoral immune response. A rational approach towards the 
development of an effective vaccine can only be made after this knowledge has been gained. 
Analysis of gpTRL12 coding sequences from clinical isolates revealed high sequence 
variability over the entire protein sequence. Phylogenetic analysis, performed on nucleotide 
and amino acid sequences, revealed that the identified variants are not randomly distributed, 
but are clearly clustered in 4 distinct groups. The four main groups diverged on the amino 
acid level in the range of 60-70%. Although the four groups showed a high degree of 
divergence, the identity within each group approaches 80-100%. Despite the impressive 
variability of the amino acid sequence, the Ig-like domain is conserved as well as the number 
and the position of cysteine residues confirming that there is a very tight constrain upon this 
domain. High variability is particularly evident in the N-terminal part of the molecule, 
predicted to be exposed,  where are concentrated most of the post-translational modifications 
sites (N- and O-glycosylation sites.). High variability associated to variation in number and 
precise location of glycosylation sites might be indicative of strong immune pressure. Altered 
patterns of glycosylation in viral proteins can be a mechanism for evasion of T cell and 
neutralizing antibody responses since it changes the phenotypic and antigenic properties of 
the virus. Further studies will be focus to find out if gpTRL12 induces neutralizing antibodies 
during natural infection and if the neutralizing ability of these antibodies is strain-specific. 
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